AURORA KINASES IN SOLELY ESTROGEN-INDUCED ONCOGENESIS: RELATION TO CENTROSOME AMPLIFICATION AND CHROMOSOMAL INSTABILITY by Hontz, Adrianne Elizabeth
AURORA KINASES IN SOLELY ESTROGEN-INDUCED 
ONCOGENESIS: RELATION TO CENTROSOME AMPLIFICATION AND 
CHROMOSOMAL INSTABILITY 
 
By 
 
Adrianne Elizabeth Hontz 
 
 
 
Submitted to the graduate degree program in Pharmacology, 
Toxicology and Therapeutics and the Graduate Faculty of the University 
of Kansas in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy. 
 
 
 
 
_________________ 
Jonathan J. Li, Chair 
 
 
________________ 
Sara Antonia Li 
 
 
_________________ 
S. J. Enna 
 
 
_________________ 
Thomas Pazdernik 
 
 
_________________ 
John Robertson 
 
 
_________________ 
Ossama Tawfik 
 
 
Date defended: May 20, 2008  
ii  
The Dissertation Committee for Adrianne Elizabeth Hontz certifies  
that this is the approved version of the following dissertation:  
 
 
 
 
AURORA KINASES IN SOLELY ESTROGEN-INDUCED 
ONCOGENESIS: RELATION TO CENTROSOME AMPLIFICATION AND 
CHROMOSOMAL INSTABILITY 
 
 
 
  
________________________  
   Chairperson  
 
 
________________________  
 
 
 
 
 
Date approved _________________ 
  
 
 
 
iii  
Acknowledgements 
I feel very fortunate to have received training filled with rewarding 
educational and research experiences. I would like to extend my utmost 
gratitude to my mentors, Drs. Jonathan and Sara Antonia Li, for their 
continued support throughout my research and the writing of this dissertation. 
The Lis have always challenged me to perform at my best and encouraged 
me to expand my knowledge and critical thinking. Their guidance has 
improved my skills as a scientist and prepared me for a successful career as 
an independent researcher.  
I would like to thank those members serving on my dissertation 
committee, Drs. S. J. Enna, John Robertson, Tom Pazdernik and Ossama 
Tawfik, for their time and scholarly input. The committee has been a great 
asset to my research project and to my scientific and professional growth. 
And to the remaining faculty of the Department of Pharmacology, Toxicology 
and Therapeutics, I thank you for providing me with a great education. From 
the Mayo Clinic, I wish to thank Dr. Jeff Salisbury, who has welcomed me into 
his lab on numerous occasions and has provided thoughtful insights towards 
my research project.  
I could not have completed this work without the love and support of 
my family, and for that I am thankful. My mother, Terri Hontz, has always 
been my biggest fan and greatest supporter. She instilled in me the 
importance of education, and watching her complete her college degree while 
iv  
I was in high school demonstrated the perseverance and hard work I would 
find to be invaluable in completing my PhD. Lastly, I would like to thank my 
loving partner, Dr. Dan Mitchum, for his support, understanding and patience 
throughout my academic endeavors. 
 
 
v  
Table of Contents 
Acceptance page…………………………………………………………………..ii 
Acknowledgements………………………………………………………………iii 
List of Figures……………...……………………………………...………………xi 
List of Tables…………….………………………………………………………..xv 
List of Abbreviations…...…………………………………….…………………xvi 
Abstract……...………..…………………………………………………………xviii 
Chapter 1: Introduction and Background……………………………………..1 
1.1 The Relationship Between Breast Cancer and Estrogen...................2 
1.2 The Syrian Hamster Model in the Study of Human Breast Cancer....6 
1.3 The ACI Rat Model in the Study of Human Breast Cancer................9 
1.4 Estrogen Action and Estrogen Receptors........................................11 
1.5 Overview of Aurora Kinases ............................................................16 
1.6 The Normal Centrosome Cycle .......................................................23 
1.7 The p53-MDM2 Pathway.................................................................26 
1.8 Centrosome Amplification, Chromosomal Instability and Aneuploidy 
in Human Breast Cancer ...............................................................30 
Chapter 2: Statement of Purpose……………………………………………..35 
2.1 Significance .....................................................................................36 
2.2 Overall Hypothesis ..........................................................................37 
vi  
2.3 Specific Aims Purpose.....................................................................38 
2.3.1 Specific Aim 1. To determine the tissue localization, 
expression, activity and regulation of the mitotic kinases, 
AurA and B, in E2-induced tumors in the Syrian hamster 
kidney……………………………………………………….38 
2.3.2 Specific Aim 2. To determine the differential 
expression/phosphorylation of selected Aur kinase 
substrates that contribute to the deregulation of the 
centrosome cycle thus causing CA and CIN during E2-
induced oncogenesis……………………………………...39 
2.3.3 Specific Aim 3. To determine whether p53wt function is 
lost due to the enhanced degradation induced by the 
over-expression of MDM2 during E2-induced 
oncogenesis, thus enhancing conditions for CA, CIN and 
oncogenic transformation…………………………………42 
Chapter 3: Materials and Methods…………………………………………….44 
3.1 Animals and treatment.....................................................................45 
3.2 Western blot ....................................................................................47 
3.3 In vitro protein kinase assay ............................................................49 
3.4 Reverse transcription PCR and quantitative real-time PCR ............49 
3.5 Immunohistochemical analysis ........................................................51 
3.6 Enrichment of amplified tumor centrosomes....................................52 
vii  
3.7 Immunofluorescence analysis .........................................................53 
3.8 Co-Immunoprecipitation ..................................................................54 
3.9 Statistical Analyses..........................................................................55 
Chapter 4: Experimental Results……………………………………………...56 
4.1 Over-expression of AurA and B and CA in early E2-induced tumor 
foci of the Syrian hamster kidney ..................................................57 
4.1.1. AurA and B expression in early tumorous foci………….57 
4.1.2. Western blot analysis of Aur A and B in control and E2-
treated kidneys and E2-induced tumors of the kidney…57 
4.1.3. AurA mRNA expression in E2-induced tumors………….58 
4.1.4. AurA activity in E2-induced tumors of the kidney……….58 
4.1.5. Estrogen modulation of the expression of the Aur kinases 
in E2-induced tumors of the kidney………………………59 
4.1.6. Western blot analysis of centrosome proteins in control 
and E2-treated kidneys and E2-induced tumors of the 
kidney……………………………………………………….60 
4.1.7. CA in E2-induced tumorous foci of the Syrian hamster 
kidney……………………………………………………….61 
4.1.8. Localization of AurA and other centrosome proteins in 
isolated amplified centrosomes from E2-induced tumors 
of the kidney………………………………………………..61 
viii  
4.2 Expression of selected Aur kinase substrates in E2-induced tumor 
foci of the Syrian hamster kidney and the ACI rat mammary gland
......................................................................................................62 
4.2.1. Tissue localization of Aur substrates in early E2-induced 
tumor foci of the kidney……………………………………62 
4.2.2. Western blot analysis of Aur substrates in control and E2-
induced tumors of the kidney……………………………..63 
4.2.3. Estrogen modulation of the expression of Aur substrates 
non- and phosphorylated in E2-induced tumors of the 
kidney……………………………………………………….64 
4.2.4. Western blot analysis of Aur substrates in control and E2-
induced tumors of the mammary gland………………….64 
4.2.5. Estrogen modulation of the expression of Aur substrates 
non- and phosphorylated in E2-induced tumors of the 
mammary gland……………………………………………65 
4.2.6. Localization of Aur substrates and other centrosome 
proteins in isolated amplified centrosomes from E2-
induced tumors of the kidney and mammary gland……65 
4.3 MDM2 expression and regulation in E2-induced tumor foci of the 
Syrian hamster kidney and the ACI rat mammary gland ...............66 
4.3.1. Western blot analysis of MDM2 and p53 in control and 
E2-induced tumors of the kidney…………………………66 
ix  
4.3.2. MDM2 and p53wt mRNA expression in E2-induced tumors 
of the kidney………………………………………………..67 
4.3.3. Estrogen modulation of MDM2 and p53 expression in E2-
induced tumors of the kidney…………………………..…67 
4.3.4. Co-immunoprecipitation of MDM2 and p53wt in E2-
induced tumors of the kidney……………………………..68 
4.3.5. RITA modulation of MDM2 and p53wt protein expression 
in E2-treated kidneys and E2-induced tumors of the 
kidney……………………………………………………….68 
4.3.6. RITA modulation of Bax and p21 protein expression in 
the kidney…………………………………………………..69 
4.3.7. Western blot analysis of MDM2 and p53 in control and 
E2-induced tumors of the mammary gland……………...70 
4.3.8. MDM2 and p53wt mRNA expression in E2-induced tumors 
of the mammary gland…………………………………….70 
4.3.9. Estrogen modulation of the expression of MDM2 and p53 
in E2-induced tumors of the mammary gland…………...71 
4.3.10. Co-immunoprecipitation of MDM2 and p53wt in E2-
induced tumors of the mammary gland………………….72 
Chapter 5: Discussion…………………………………………………………119 
5.1 General Discussion .......................................................................120 
5.2 Overall Conclusions.......................................................................124 
x  
5.3 Future Directions ...........................................................................134 
References……………………………………………………………………….136 
 
xi  
List of Figures 
Figure 1. Schematic representation of the Syrian hamster germinal ridge 
(Adapted from (Li et al., 2001) ......................................................7 
Figure 2. Schematic representation of ER/estrogen mediated gene 
transcription. Estrogen (E2), estrogen receptor (ER), heat shock 
protein (HSP) (Adapted from (Michalides, Griekspoor et al. 2004)
....................................................................................................15 
Figure 3. Schematic representation of the three human Aurora kinases. The 
numbers on the right indicate the proteins percentage sequence 
identities. (Adapted from ((Keen and Taylor, 2004; Nguyen et al., 
2005)) .........................................................................................17 
Figure 4. Localization of AurA and B kinase during mitosis (Adapted from 
(Carmena and Earnshaw, 2003).................................................19 
Figure 5. The normal centrosome cycle.....................................................26 
Figure 6. The p53 pathway ........................................................................28 
Figure 7. Immunostaining of AurA and B in Syrian hamster E2-induced early 
tumor foci of the kidney...............................................................73 
xii  
Figure 8. Effect of estrogen treatment on the protein expression of AurA 
and B in the Syrian hamster kidney ............................................75 
Figure 9. Effect of estrogen treatment in the mRNA expression of AurA by 
real-time PCR in the Syrian hamster kidney ...............................77 
Figure 10.   Effect of estrogen treatment on AurA kinase activity in the Syrian 
hamster kidney and in E2-induced tumors of the kidney .............79 
Figure 11.   Estrogen modulation of Aur kinase protein expression in the 
Syrian hamster E2-induced tumors of the kidney ........................81 
Figure 12. Effect of estrogen treatment in the protein expression of centrin 
and γ-tubulin in the Syrian hamster kidney and in E2-induced 
tumors of the kidney ...................................................................83 
Figure 13. Effect of E2 in centrosome number and size in Syrian hamster 
tumor foci of the kidney...............................................................85 
Figure 14. Localization of AurA and centrosome proteins, γ-tubulin and 
centrin, to isolated centrosome fractions of Syrian hamster E2-
induced tumors of the kidney ......................................................87 
Figure 15. Effect of estrogen treatment on the protein expression of TPX2 in 
Syrian hamster tumor foci of the kidney......................................89 
xiii  
Figure 16. Protein expression of centrin, histone H3, PP1 and TPX2 in 
Syrian hamster E2-induced tumors of the kidney ........................91 
Figure 17. Estrogen modulation of the protein expression of centrin and 
histone H3 in Syrian hamster E2-induced tumors of the kidney ..93 
Figure 18. Protein expression of centrin, histone H3, PP1 and TPX2 in ACI 
rat mammary glands and in E2-induced mammary tumors .........95 
Figure 19. Estrogen modulation of the protein expression of centrin and 
histone H3 in ACI rat mammary glands and in E2-induced 
mammary tumors........................................................................97 
Figure 20. Effect of estrogen treatment in the protein expression of MDM2 
and p53 in the Syrian hamster kidney and in E2-induced tumors of 
the kidney ...................................................................................99 
Figure 21. Effect of E2 in the mRNA expression of MDM2 and p53wt, 
measured by real-time PCR, in the Syrian hamster kidney.......101 
Figure 22. Estrogen modulation of the protein expression of MDM2 and p53 
in Syrian hamster E2-induced tumors of the kidney ..................103 
Figure 23. Binding of p53wt and MDM2 in Syrian hamster kidneys and in E2-
induced tumors of the kidney ....................................................105 
xiv  
Figure 24. Effect of the MDM2 inhibitor RITA on the protein expression of 
MDM2 and p53 in Syrian hamster kidneys and in E2-induced 
tumors of the kidney .................................................................107 
Figure 25. Effect of the MDM2 inhibitor RITA on the protein expression of 
Bax and p21 in Syrian hamster kidneys and in E2-induced tumors 
of the kidney .............................................................................109 
Figure 26. Protein expression of MDM2 and p53 in ACI rat mammary glands 
and in E2-induced mammary tumors.........................................111 
Figure 27. mRNA expression of MDM2 and p53wt, measured by real-time 
PCR, in ACI rat mammary glands and E2-induced mammary 
tumors.......................................................................................113 
Figure 28. Estrogen modulation of MDM2 and p53 protein expression in ACI 
rat mammary glands and in E2-induced mammary tumors .......115 
Figure 29. p53wt and MDM2 binding in ACI rat mammary glands and in E2-
induced mammary tumors ........................................................117 
Figure 30. Schematic representation of the proposed pathway of events 
leading to neoplastic transformation during E2-induced 
oncogenesis..............................................................................122 
xv  
List of Tables 
Table 1. Breast Cancer risk factors .................................................................3 
Table 2. Known substrates of AurA and B.....................................................21 
 
xvi  
List of Abbreviations 
ACI: August Copenhagen Irish 
ADH: atypical ductal hyperplasia 
AF: activation function 
ANOVA: Analysis of Variance 
APC: anaphase promoting complex 
ATP: adenosine 5’-triphosphate 
Aur: Aurora kinase 
BC: breast cancer 
BRCA: breast cancer gene 
CA: centrosome amplification  
Cdk: cyclin dependant kinase 
CIN: chromosomal instability 
COC: combination oral contraceptive 
DCIS: ductal carcinoma in situ 
DES: diethylstilbestrol 
E2: 17β-estradiol 
ER: estrogen receptor 
ERE: estrogen response element 
ERT: estrogen replacement therapy 
G1, 2: gap phases of the cell cycle 
H&E: hematoxylin and eosin 
xvii  
HRT: hormone replacement therapy 
IDBC: invasive ductal breast cancer 
M: mitosis 
MDM2: mouse double minute 2 
MIN: microsatellite instability 
NEK: nima related kinase 
PCR: polymerase chain reaction 
PP1: protein phosphatase 1 
RITA: Reactivation of p53wt and Induction of Tumor cell Apoptosis 
S: DNA synthesis phase of the cell cycle 
SERM: selective estrogen receptor modulator 
SNP: single nucleotide polymorphism 
TPX2: targeting protein for Xklp2 
Tx: tamoxifen citrate 
 
 
xviii  
Abstract 
Persistent Aurora (Aur) A and B over-expression, centrosome 
amplification (CA), chromosomal instability (CIN) and aneuploidy invariably 
occur together in a vast majority of human neoplasms. These molecular 
changes are frequently found (>80%) in human sporadic ductal carcinoma in-
situ (DCIS) and in primary invasive ductal breast cancers (IDBC). In solely 
17β-estradiol (E2)-induced mammary tumors in ACI rats, Li et al. have 
previously shown AurA protein over-expression, CA, CIN and aneuploidy (Li 
et al., 2004). AurA and B, mitotic kinases involved in controlling proper cell 
division, are modulated by cell cycle progression. Their over-expression is 
implicated in the deregulation of chromosomal duplication/segregation, and 
cytokinesis leading to CA, CIN and aneuploidy. To determine whether the 
over-expression of Aur kinases is a common feature of E2-induced 
oncogenesis, AurA and B expression were examined in the Syrian hamster 
tumors of the kidney. Western blot analysis of the E2-induced Syrian hamster 
tumors of the kidney revealed that both AurA and B protein expression was 
markedly increased when compared to cholesterol-treated controls. 
Moreover, immunohistochemistry revealed that this increase in AurA and B 
expression was specifically localized to E2-induced tumor cells. Using an in 
vitro kinase assay, a significant increase in AurA kinase activity was detected 
in these tumors of the kidney and a significant increase in AurA mRNA levels 
xix  
was detected as measured by real-time PCR. The over-expression of both 
kinases was markedly reduced in E2-induced tumor-bearing hamsters 
subjected to either a 10-day E2-withdrawal period or treated for a similar 
period with Tamoxifen citrate (Tx) plus E2, when compared to tumors of the 
kidney from hamsters treated with E2 alone. These results indicate that both 
AurA and B are under estrogen control mediated by estrogen receptor α 
(ERα). Additionally, examination of centrin and γ-tubulin expression in Syrian 
hamster tumors of the kidney indicates an increase in centrosome number 
and size, a characteristic of CA. The AurA expression was co-localized to 
isolated amplified tumor centrosomes, identified by their high levels of centrin 
and γ-tubulin expression. CIN and aneuploidy in Syrian hamster tumors of the 
kidney has previously been demonstrated (Papa et al., 2003). In order to 
assess, during E2-induced oncogenesis, whether the over-expression of AurA 
and B contributes to the deregulation of the centrosome cycle via their 
specific protein substrates, we analyzed the protein expression of centrin, 
histone H3, PP1 and TPX2, all of which were significantly over-expressed in 
Syrian hamster tumors of the kidney and in ACI rat mammary gland tumors. 
Additionally, the expression of MDM2, which regulates the tumor suppressor 
gene p53, and p53 protein, an AurA substrate, were examined in Syrian 
hamster tumors of the kidney and in ACI rat mammary gland tumors. MDM2 
expression was significantly increased in both Syrian hamster tumors of the 
kidney and in ACI rat mammary gland tumors at the protein and mRNA level, 
xx  
and estrogen modulation studies showed that MDM2 protein expression is 
either directly or indirectly controlled by E2. Binding studies show that MDM2 
is bound to p53wt. MDM2-p53wt binding was inhibited in Syrian hamster 
tumors of the kidney after treatment with the small molecule inhibitor RITA 
(Reactivation of p53 and Induction of Tumor cell Apoptosis). In E2-induced 
Syrian hamster tumors of the kidney, Western blot analysis revealed that 
RITA treatment led to a significant increase in p53wt protein expression when 
compared to untreated tumor samples. In addition, RITA treatment led to the 
increased expression of Bax, a downstream target gene of p53, which 
promotes apoptosis. These data suggest that Aur kinase over-expression, 
induced by estrogens, may interfere with bipolar spindle formation and 
chromosome segregation, leading to CA, CIN and aneuploidy, thus 
supporting the concept that AurA over-expression and CA are causative 
events, induced by estrogen, that lead to tumor development. The over-
expression of MDM2, in tandem with AurA, indicates a close relationship 
between these two entities in fostering CA, CIN, aneuploidy and tumor 
development, defining events of E2-driven oncogenesis. 
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Chapter 1: Introduction and Background 
2  
1.1 The Relationship Between Breast Cancer and Estrogen 
Breast cancer (BC) is the most commonly diagnosed female cancer 
worldwide with an estimated one million new cases diagnosed each year 
(Bray et al., 2004). Moreover, BC is the second leading cause of cancer 
related deaths in industrialized countries (Nkondjock and Ghadirian, 2005). 
Approximately 181,000 cases of BC are diagnosed in the United States each 
year with an estimated 41,000 dying from BC each year  (2007). It has been 
well established that cancer has a genetic basis; however, only 5 – 10% of 
BC are familial (King et al., 1993). These familial cases largely result from 
inherited mutations in BC susceptibility genes such as BRCA1 and 2 (2005). 
In the case of sporadic BC, which accounts for about 90 – 95% of all BC 
cases, it has been well established that both endogenous, and to a lesser 
extent, exogenous estrogens play a crucial role in both the causation and 
development (Bilimoria and Morrow, 1995).  
In addition to being female and post-menopausal (50+ years), the 
major risk factors of sporadic BC are associated with ovarian hormone 
exposure (Table 1), more specifically, the accumulation of a woman’s lifetime 
exposure to estrogen (Bernstein, 2002). These well-established risk factors 
include:  early age of menarche (<12 years), late onset of menopause (>55 
years), nulliparity, late age of first full-term birth (>30 years) and fewer number 
of full-term births (Martin and Weber, 2000; 2005). All of these risk factors act 
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to directly increase a woman’s exposure to circulating levels of estrogen 
through an increased number of uninterrupted ovulatory cycles.   
Table 1. Breast Cancer risk factors 
Early age of menarche Post-menopausal obesity 
Late onset of menopause Alcohol consumption 
Nulliparity Physical inactivity 
Late age of first full-term birth COC / HRT 
Fewer number of full-term births Ovarian tumors 
 
Other risk factors associated with BC may be attributed to individual 
diet and lifestyle choices which have been shown to indirectly increase 
endogenous levels of circulating estrogens. Obesity increases a woman’s risk 
of post-menopausal BC (McPherson et al., 2000; Eliassen et al., 2006); 
however it does not increase the risk of pre-menopausal BC (Huang et al., 
1997). In post-menopausal women, adipose tissue is the major source of 
circulating estrogen. Thus, obesity increases the level of estrogen and the 
likelihood of developing BC. Physical activity has been implicated as an 
important variable risk factor for BC (Colditz et al., 2003). An inverse 
association between physical activity and BC has been reported (Bernstein et 
al., 2005). In addition, moderate alcohol consumption (1-2 drinks per day) has 
been associated with a 30-50% increase in BC  (Martin and Weber, 2000; 
Terry et al., 2006). It has been suggested that alcohol consumption within the 
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last five years is associated with an 82% increased risk in young women (age 
20-49) relative to never drinkers (Berstad et al., 2007).  
Other proposed BC risk factors are related to the exogenous 
administration of estrogens such as in combination oral contraceptives (COC) 
and hormone replacement therapy (HRT). While one may expect that the 
ingestion of these exogenous estrogens would increase a woman’s risk of 
BC, a majority of studies report only a modest increase in BC risk in a subset 
of COC users under the age of 45 (Malone et al., 1993). A slight increase in 
the risk of developing BC has been reported in women taking COCs and 10 
years after cessation (McPherson et al., 2000). However, recent reports 
suggest that, at most, COC use is a minor BC risk contributor (Nichols et al., 
2007).  
Estrogen replacement therapy (ERT) or combined HRT provide relief 
of menopausal symptoms and prevent osteoporosis in post-menopausal 
women, thus leading to their increased use in recent decades (Keating et al., 
1999). Over the last 10 years, both therapies have come under fire for their 
suspected role in increasing BC risk. Several reports have shown data in 
favor of (Colditz et al., 1995; Schairer et al., 2000; Beral, 2003) and against 
(Dupont and Page, 1991) an increased BC risk after these post-menopausal 
hormone therapies. The most comprehensive of these studies, the Women’s 
Health Initiative, a randomized, double-blind, placebo controlled disease 
prevention trial, reported no increase in BC risk in women taking ERT alone 
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(Anderson et al., 2004). However, women receiving combined HRT were 26% 
more likely to develop BC (Rossouw et al., 2002) and to be diagnosed at an 
advanced stage most likely due to an increase in breast density which 
delayed diagnosis (Chlebowski et al., 2003). 
Additional strength for the link between BC and estrogen has been 
observed in some of the drugs used in its therapy. The two types of hormonal 
therapies used in the treatment of BC include selective estrogen receptor 
modulators (SERMs) and aromatase inhibitors. SERMs are used for 
treatment and prevention of BC in both pre- and post-menopausal women, 
whereas aromatase inhibitors are used for prevention only in post-
menopausal women. SERMs, like tamoxifen, work by selectively inhibiting 
estrogen receptor α (ERα). The binding of tamoxifen to the ERα results in a 
conformational change which favors recruitment of co-repressors that inhibit 
transcription (Come et al., 2005). In at-risk populations, tamoxifen is effective 
in preventing cancer cell proliferation and reducing BC incidence by 48% 
(Johnston, 2005). Aromatase inhibitors have been shown to be effective in 
reducing serum estrogen levels by inhibiting the conversion of androgens to 
estrogens in peripheral tissues (Fentiman, 2004). While tamoxifen has been 
the standard of care for several decades, recent studies have shown that 
treatment with aromatase inhibitors may be more efficacious as a first–line 
treatment of advanced BC (Baum et al., 2002).  
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1.2 The Syrian Hamster Model in the Study of Human Breast 
Cancer 
Estrogen-induced tumors of the Syrian hamster kidney were first 
described in 1959 by Kirkman (Kirkman, 1959). He showed that these tumors 
were not only estrogen-induced but also estrogen-dependent. When the 
estrogen source was removed, the tumors stopped growing and underwent a 
marked regression (Kirkman, 1959). The Syrian hamster kidney is an 
intensively studied model in estrogen oncogenesis because 100% tumor 
incidence is achieved using the natural hormone 17β-estradiol (E2) in the 
absence of co-administration of any other carcinogen (Liehr, 1997). 
Moreover, no spontaneous tumors have been detected at this organ site 
(Kirkman, 1959; Pour et al., 1976). 
In development, the hamster reproductive tract and urinary tract 
systems arise from the same germinal ridge of multipotential cells (Kirkman, 
1959; Li et al., 2001) (Figure 1). Some of the reproductive germinal cells that 
are normally destined to reside in the uterus ectopically migrate to the urinary 
tract where they establish themselves in the corticomedullary region of the 
kidney. These misplaced interstitial cells, committed to an epithelial 
differentiation pathway, are referred to as ectopic uterine stem cells (Li et al., 
2001). These cells remain dormant unless exposed to a sustained level of 
estrogen. 
7  
Figure 1. Schematic representation of the Syrian hamster germinal 
ridge (Adapted from (Li et al., 2001) 
 
Bilateral tumors can be induced with E2 and the synthetic estrogen 
diethylstilbestrol (DES) in both intact and castrated male hamsters. Similar 
tumors can also be induced in ovariectomized female hamsters, but because 
frequent estrogen exposure induces aplastic anemia in female hamsters 
resulting in a high mortality, they are not commonly used. Moreover, intact 
females do not develop kidney tumors when exposed to E2/DES alone 
because of the inhibitory effects of ovarian progesterone (Kirkman, 1959). 
This response is in contrast to the role of this hormone in the mammary gland 
8  
where both estrogen and progesterone are mitogenic. Progestins, anti-
estrogens, like tamoxifen, and androgens, when concomitantly administered 
with E2 or DES completely block the formation of these tumors in the hamster 
kidney (Li and Li, 1978).  
An advantage of this well-established animal model is that E2-induced 
tumors occur in the absence of any intervening morphological stages, and the 
tumors develop via the continuous progression of a subset of interstitial stem 
cells (Li et al., 2003b). This is a marked contrast to human BC and other 
female rat E2-induced mammary tumors from a variety of strains which 
progress through stages of hyperplasia, atypical ductal hyperplasia (ADH), 
dysplasia and ductal carcinoma in-situ (DCIS) in response to continuous 
estrogen exposure. However, the E2-induced Syrian hamster kidney model 
and human BC share many crucial early molecular changes (Li and Li, 2003). 
These events include: over-expression and amplification of early response 
nuclear proto-oncogenes c-myc, c-fos and c-jun (Hou et al., 1996; Li et al., 
1999), deregulation of cell-cycle entities including cyclins D and E, cyclin 
dependent kinase (cdk) 2 and 4, pRb and the cyclin dependent kinase 
inhibitor p27 (Liao et al., 2000), AurA/B over-expression (Hontz et al., 2007), 
CA, CIN and aneuploidy (Li et al., 2001).  
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1.3 The ACI Rat Model in the Study of Human Breast Cancer  
Rodent models have been used in the study of human BC since the 
1930s (Lacassagne, 1932; Lacassagne, 1933). Many studies have identified 
mouse and rat strains highly susceptible to estrogen-induced mammary 
carcinogenesis (Dunning et al., 1953; Nagasawa, 1979). However, these 
solely estrogen-induced mammary tumor models are limited by variability in 
tumor incidence depending on the strain, administration method, dose and 
tolerance (Dunning et al., 1953). Several of the rat tumor models become 
estrogen-dependent upon treatment with synthetic chemical carcinogens, 
including 7,12-dimethylbenz-(a)anthracene (DMBA) (Huggins et al., 1961) 
and methylnitrosourea (MNU) (Bots and Willighagen, 1975), or radiation to 
induce tumor development. While these chemically-induced rat mammary 
tumors are morphologically similar to human BCs (Russo and Russo, 2000; 
Singh et al., 2000), the cellular sequence is not the same, no ADH or DCIS, 
and they do not share the same molecular characteristics. For example, 
chemically-induced rat mammary tumors are highly diploid (>85%) (Aldaz et 
al., 1992; Haag et al., 1996), whereas human BCs are highly aneuploid, 
89.6% (Arnerlov et al., 2001). The validity of these chemically-induced tumor 
models has also been questioned because their induction requires synthetic 
chemicals to which women are never exposed to in the environment. 
The August Copenhagen Irish (ACI) rat, a cross between the August 
and the Copenhagen-Irish strains has emerged as a uniquely sensitive, solely 
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estrogen-induced mammary oncogenesis model (Dunning et al., 1953). 
Recently, the sensitivity of the ACI strain to estrogen-induced BC has been 
mapped to chromosomes 5 and 18 (Gould et al., 2004). These chromosomes 
are the location of estrogen-induced mammary cancer (Emca) 1 and 2 genes 
which act independently to increase tumor incidence and decrease latency. 
ACI rat mammary tumors are both estrogen-induced and -dependent as 
demonstrated by tumor regression when exogenous estrogen sources are 
removed or anti-estrogens are co-administered (Li et al., 2002b). Advantages 
of this model over other mouse and rat models include: 1. Estrogen treatment 
of intact female ACI rats causes mammary tumors in 100% of the animals 
within 6 months (Li et al., 2002b); 2. There is a very low incidence of 
spontaneous mammary gland tumor development – about 11% (Maekawa 
and Odashima, 1975); 3. A rat mammary tumor virus has not been identified 
as is the case in mice with the mouse mammary tumor virus (MMTV); 4. 
Estrogen concentrations used to induce tumor formation approach the 
physiological range of normal cycling rats (70-80 pg/mL) (Li et al., 2004); 5. 
Concomitant treatment with SERMs, like tamoxifen, completely inhibits E2-
induced mammary tumor induction (Li and Li, 2003); 6. Histopathologic and 
morphological changes including: hyperplasia, dysplasia, DCIS and invasive 
ductal breast cancer (IDBC) are similar to those reported in human BC; and 7. 
Cellular and molecular features observed in E2-induced ACI rat mammary 
tumors are similar to those observed in human ductal BC. For example, both 
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ACI rat mammary tumors and human BCs frequently show over-expression 
and amplification of early response nuclear proto-oncogenes c-myc (Li et al., 
2002a), c-fos and c-jun, deregulation of cell-cycle entities including cyclins D1 
and E1 (Weroha et al., 2006), cdk2 and 4, pRb and the cyclin dependent 
kinase inhibitor p27, AurA/B over-expression, CA, CIN and aneuploidy (Li et 
al., 2004).  
 
1.4 Estrogen Action and Estrogen Receptors 
Natural estrogens are steroid hormones synthesized from cholesterol, 
in the ovaries and adrenal gland. The synthesis and secretion of estrogens 
are controlled by follicle stimulating hormone produced by the pituitary gland. 
Estrogen is used to collectively describe the female hormones which include 
E2, estrone and estriol. Of these, E2 is the most abundant and potent. 
Estrogens influence growth, differentiation and functioning of target tissues 
including mammary gland, uterus and ovaries (Kuiper et al., 1997). Estrogens 
have also been shown to play a role outside the reproductive system. They 
play an important role in bone maintenance (Srivastava et al., 2001), brain 
function (McEwen, 1999) and the cardiovascular system where, depending on 
the E2 levels, they may exert cardioprotective effects (Mendelsohn and Karas, 
1999).  
Estrogen displays its effects through at least four estrogen receptor 
(ER) pathways: classical ligand-dependent, ligand-independent, estrogen 
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response element (ERE)-independent and cell-surface (non-genomic) 
signaling (Hall et al., 2001). The classical mechanism of estrogen action, via 
ERs, is how most of its biological effects occur. Estrogens circulate in the 
body either un-bound or bound to albumin or sex hormone binding globulin 
(Kahn et al., 2002). Un-bound estrogen can freely diffuse in and out of cells; 
however, in target cells, estrogen is retained with high affinity and specificity 
by binding to ERs (Kuiper et al., 1997). This binding allows the ERs to 
dissociate from a heat shock protein and undergo a conformational change 
allowing dimerization to occur. The ER dimers can then bind to specific 
sequences of DNA referred to as EREs that act as transcription factors used 
to modulate transcription of target genes (Figure 2). The interaction with 
EREs can be direct or indirect via the action of co-activators which enhance 
transcription (McKenna et al., 1998) or co-repressors which down-regulate 
transcription (Dobrzycka et al., 2003).  
ERs belong to the steroid/thyroid hormone superfamily of nuclear 
receptors. Two ERs have been identified, ERα  by Jensen in 1958 (Jensen 
and DeSombre, 1973) and ERβ by Kuiper in 1996 (Kuiper et al., 1996). ERα 
and ERβ are separate gene products; ERα is localized to human 
chromosome 6q25.1 (Menasce et al., 1993) and ERβ to chromosome 14q22-
24 (Enmark et al., 1997). The ERs can be subdivided into several functional 
domains, the highly conserved, 97 and 60% DNA- and ligand binding 
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domains, respectively, and the highly variable N-terminal domain (Hall et al., 
2001).  
Both ERs are widely distributed throughout the body. ERα is 
expressed primarily in the pituitary, uterus, liver, heart and kidneys, whereas 
ERβ is expressed primarily in the lungs, ovary, prostate, gastrointestinal tract, 
bladder as well as hematopoietic and central nervous systems (Couse et al., 
1997; Kuiper et al., 1997). ERα and ERβ are co-expressed in the mammary 
gland, epididymis, thyroid, adrenal, bone and certain regions of the brain 
(McEwen and Alves, 1999; Pettersson and Gustafsson, 2001). In many 
instances, when co-expressed, ERβ opposes the actions of ERα. The 
function of ERα is primarily related to cellular growth responses in target 
tissues, whereas the function of ERβ is primarily anti-proliferative and pro-
differentiative (Imamov et al., 2005). 
The existence of two ER subtypes allows estrogen to signal via three 
potential nuclear pathways: ERα homodimers, ERα/ERβ heterodimers and 
ERβ homodimers (Kuiper and Gustafsson, 1997). The transactivating 
functions of ERα and ERβ are mediated by transcription activation functions 
(AF-1 and AF-2) that allow the ERs to stimulate the transcription of estrogen-
regulated genes. In addition to their role in transcription mediation, AFs 
mediate cell- and promoter-specificity (Matthews and Gustafsson, 2003). 
While both ERs are highly reactive to activation through the ligand-dependent 
AF-2, only ERα is highly reactive to ligand-independent activation through AF-
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1. It has been suggested that this weaker activation of ERβ through AF-1 
might be the origin of its repressive activity (Ogawa et al., 1998).  
In addition to the nuclear ER, a G protein-coupled ER, GPR30, has 
been described (Carmeci et al., 1997). In response to estrogen, GPR30 can 
mediate rapid signaling events and modulate transcriptional activity. In a 
recent clinical study of human breast samples 42% and 62% of DCIS and 
IDBC were GRP30 positive, respectively (Filardo et al., 2006). While it is as 
yet unknown how ER and GPR30 interact and the role that this interaction 
may play in oncogenesis, GPR30 may represent an important mechanism to 
overcome ER loss in BC (Prossnitz et al., 2008). 
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Figure 2. Schematic representation of ER/estrogen mediated gene 
transcription. Estrogen (E2), estrogen receptor (ER), heat shock protein 
(HSP) (Adapted from (Michalides, Griekspoor et al. 2004) 
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1.5 Overview of Aurora Kinases  
Aurora kinases are mitotic serine/threonine kinases that phosphorylate 
a myriad of mitotic/centrosomal protein substrates required for proper 
chromosome duplication, segregation and cytokinesis. These mitotic events 
are important in maintaining genomic integrity. The serine/threonine family of 
mitotic kinases also includes cdk1, the polo-like kinases with four family 
members, the NEK kinases with 11 family members and the WARTS/LATS 1 
related kinases (Marumoto et al., 2005). 
Aurora kinases were first discovered in Drosophila (Glover et al., 
1995); however, human tissue samples have been reported to express three 
Aurora kinases  (Keen and Taylor, 2004) (Figure 3). Because numerous 
research groups discovered the various Aurora proteins independently, they 
are known by a plethora of names; however, nomenclature has agreed on 
Aurora A (AurA), B (AurB) and C (AurC) (Adams et al., 2001; Nigg, 2001). 
The catalytic domains of the Aurora kinases (Figure 3, shown in green) are 
highly conserved, but there is little homology between the NH2-terminal 
extensions. Auto-phosphorylation of a threonine residue in the T-loop, (Figure 
3, shown in yellow) is required for the activation of the protein’s kinase 
activity. The destruction box (D-box), (Figure 3, shown in blue) is a short 
amino acid motif that is recognized by adaptors of the anaphase promoting 
complex (APC). These adaptors target the protein for degradation via the 
ubiquitin pathway. AurA degradation is dependent upon an intact A- and D-
17  
box (Littlepage and Ruderman, 2002; Keen and Taylor, 2004). AurB is 
degraded by the proteasome via the Cdc27 subunit of the APC. Degradation 
of AurB does not depend on its D-box, but it does require intact KEN- and A-
boxes (Nguyen et al., 2005). While AurA and B are expressed in most cell 
types, AurC is specifically expressed in the testis where it plays a role in 
spermatogenesis (Carmena and Earnshaw, 2003; Marumoto et al., 2005).  
Figure 3. Schematic representation of the three human Aurora 
kinases. The numbers on the right indicate the proteins percentage 
sequence identities. (Adapted from ((Keen and Taylor, 2004; Nguyen et 
al., 2005)) 
 
Although the catalytic domains of the Aurora kinases are highly 
conserved, they have very distinct subcellular localizations (Carmena and 
Earnshaw, 2003). While AurA maintains an association with the centrosomes, 
AurB is a chromosomal passenger protein that migrates during mitosis 
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(Figure 4). In G1, the levels of both AurA and B are significantly reduced. By 
prophase, AurA is at the centrosomes whereas AurB is nuclear. In 
metaphase, AurA is on the microtubules near the spindle poles and AurB is 
on the centromeres. As the cells progress to anaphase, the majority of AurA 
is on the polar microtubules and AurB is at the spindle midzone. However, at 
the culmination of the cell cycle, both AurA and B are at the cell midbody 
where they participate in cytokinesis. 
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Figure 4. Localization of AurA and B kinase during mitosis (Adapted 
from (Carmena and Earnshaw, 2003) 
 
20  
AurA and B are essential for the proper execution of various mitotic 
events. The mitotic roles of AurA and B have been elucidated using 
techniques such as Aur-depletion, -inhibition and RNA interference (RNAi). 
AurA plays a role in centrosome duplication, maturation and separation, 
mitotic entry, bipolar spindle assembly and stability, chromosome alignment 
and cytokinesis, whereas AurB participates in phosphorylation of histone H3, 
chromosome alignment, chromosome segregation and cytokinesis. AurB 
binds three other chromosomal passenger proteins: inner centromere protein 
(INCENP), survivin and borealin (Keen and Taylor, 2004). Proper localization 
and function of any of these proteins is dependent on the other three. 
Substrates for both AurA (Mendez et al., 2000; Katayama et al., 2001; Du and 
Hannon, 2002; Giet et al., 2002; Gigoux et al., 2002; Kufer et al., 2002; Sakai 
et al., 2002; Castro et al., 2003; Hirota et al., 2003; Kunitoku et al., 2003; 
Dutertre et al., 2004; Katayama et al., 2004; Ouchi et al., 2004; Tien et al., 
2004; Toji et al., 2004; Troiani et al., 2005) and AurB (Giet and Glover, 2001; 
Zeitlin et al., 2001; Bishop and Schumacher, 2002; Rogers et al., 2002; Goto 
et al., 2003; Kawajiri et al., 2003; Minoshima et al., 2003; Lan et al., 2004; 
Guse et al., 2005; Delacour-Larose et al., 2007) have been identified (Table 
2), yet whether all of these substrates are actually phosphorylated in vivo 
remains to be determined. The expression of both AurA and B peaks at the 
G2/M transition and kinase activity is maximal during mitosis (Katayama et 
al., 2003). 
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Table 2. Known substrates of AurA and B. Common substrates to both 
are bolded. 
AurA substrates 
Ajuba Eg5 p53 
BRCA1 Hec 1 PP1 
CDC25B Histone H3 Ras GAP 
Cdh-1 hsNuf2 TACC 
CENP-A/B Lats2 TPX2 
Centrin 2 MBD3 Survivin 
CPEB NM23-H1 Vimentin 
 
AurB substrates 
CENP-A INCENP Myosin II 
Desmin MCAK Survivin 
GFAP MgcRacGAP Topoisomerase IIα 
Histone H3 MKLP1 Vimentin 
 
Presently, the most extensively studied Aurora kinase is AurA. Ectopic 
expression of AurA, active or not, leads to CA (Zhou et al., 1998; Meraldi et 
al., 2002). The over-expression of kinase active AurA has the ability to 
transform NIH3T3 cells and when implanted in nude mice induces tumor 
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formation, thus supporting the role of AurA as an oncogene (Bischoff et al., 
1998; Zhou et al., 1998). While it appears that over-expression of AurA is 
sufficient to deregulate the centrosome cycle leading to centrosome 
abnormalities, its kinase activity is necessary to cause transformation leading 
to tumor formation.  
AurA over-expression has been reported in hematological tumors and 
nearly all human solid tumors including: liver with a frequency or 61% (Jeng 
et al., 2004), esophageal with a frequency of 58% (Tong et al., 2004), lung 
(Haruki et al., 2001), gastric with a frequency of 50% (Sakakura et al., 2001), 
prostate (Bar-Shira et al., 2002), non-Hodgkins lymphoma (Yakushijin et al., 
2004), bladder with a frequency of 75% (Sen et al., 2002), pancreatic with a 
frequency of 58% (Han et al., 2002; Li et al., 2003a), colorectal with a 
frequency of 50% (Bischoff et al., 1998), kidney with a frequency of 95% 
(Ehara et al., 2003), ovarian with a frequency of 57% (Gritsko et al., 2003), 
endometrial (Moreno-Bueno et al., 2003) and breast (Tanaka et al., 1999). Of 
note, reports indicate that AurA is over-expressed with a frequency of 94% in 
human DCISs and primary invasive mammary carcinomas (Tanaka et al., 
1999) coming in second only behind kidney tumors (Ehara et al., 2003). 
Interestingly, AurA over-expression is not commonly correlated with gene 
amplification indicating that other mechanisms such as transcriptional 
activation and suppression of protein degradation must also play a role in 
AurA regulation (Marumoto et al., 2005). While significantly less is known 
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about AurB and its role in oncogenesis, it is known that AurA and B 
expression levels appear to rise or decline in parallel (Keen and Taylor, 
2004). While no direct link has as yet been found between AurA over-
expression and centrosome abnormalities, AurA overexpression, CA and 
aneuploidy invariably occur together.  
The over-expression of Aurora kinases has been strongly linked to 
oncogenesis as well as tumor proliferation. This has led to the development of 
a new class of anti-cancer drugs that specifically targets the ATP-binding 
domain of the Aurora kinases. Currently, eight novel Aurora kinase inhibitors 
have been described. Of these, VX-680 (Harrington et al., 2004) has shown 
promising results both in vitro and in vivo and is the first Aurora kinase 
inhibitor to enter clinical trials. The high frequency of AurA over-expression, 
~94%, in human BC (Tanaka et al., 1999) and in the ACI rat E2-induced 
mammary tumors (Li et al., 2004), provides strong evidence that small 
molecule inhibitors like VX-680 may provide a new approach to BC therapy.  
 
1.6 The Normal Centrosome Cycle 
Centrosomes are cellular organelles located in the cytoplasm adjacent 
to the nucleus. They consist of a pair of barrel shaped centrioles composed of 
a radial array of nine microtubule triplets and a surrounding halo of protein 
dense pericentriolar matrix (Delattre and Gonczy, 2004). The pericentriolar 
matrix contains γ-tubulin ring complexes where microtubule nucleating activity 
24  
resides. In eukaryotic cells, the centrosome functions as the major 
microtubule organizing center (MTOC), the focal point from which 
microtubules emanate. Therefore, the centrosome influences all microtubule 
dependent processes including organelle transport, cell shape, polarity and 
motility (Meraldi and Nigg, 2002). Other important functions of the 
centrosomes occur during mitosis, when the centrosomes aid in establishing 
a bipolar spindle apparatus and cytokinesis (Wang et al., 2004). 
In normal cells, centrosomes duplicate only once in each cell cycle to 
give rise to two mitotic spindle poles. The centrosome cycle has been divided 
into a series of discrete events commonly referred to as centriole 
disengagement, centriole duplication, centrosome maturation and centrosome 
separation (Meraldi and Nigg, 2002). Centrosome duplication is closely 
coordinated with the stages of the cell cycle (Figure 5). The interphase 
centrosome consists of a pair of centrioles surrounded by pericentriolar 
matrix. Duplication begins in S phase when the two centrioles lose their 
orthogonal arrangement in a process termed centriole disengagement that 
requires the protease separase (Tsou and Stearns, 2006). Centrin, a 
ubiquitous centrosome protein component, is required for centriole duplication 
(Salisbury et al., 2002) which begins with the formation of procentriole buds at 
the proximal end of each of the original centrioles. The procentrioles mature 
during S phase and G2. The separation of the two mature centrosomes 
occurs at the G2/M transition. The two mature centrosomes separate from 
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each other and move to opposite ends of the cell where they establish the 
bipolar mitotic spindle which helps ensure that chromosomes are equally 
segregated during mitosis. 
While the mechanism by which the centrosome is duplicated during 
cell division is largely unknown, it remains an active area of research. A large 
body of evidence has accumulated suggesting that centrosome duplication is 
tightly linked to cell cycle progression through interacting regulatory 
pathways. These regulators include cdk2/cyclin A and E which control the 
cell, centrosome and DNA cycles and have been implicated in triggering 
centriole duplication (Hinchcliffe et al., 1999; Lacey et al., 1999; Matsumoto et 
al., 1999; Meraldi et al., 1999; Tsou and Stearns, 2006). In addition, the 
mitotic kinases, Aurora, Polo and Nek families, have been implicated in 
centriole duplication (Meraldi and Nigg, 2001; Barr et al., 2004) as has the 
APC which ensures that centrioles duplicate only once per cell cycle (Tsou 
and Stearns, 2006). 
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Figure 5. The normal centrosome cycle 
 
 
1.7 The p53-MDM2 Pathway 
p53 is a tumor suppressor protein which plays an important role in 
protecting the genomic stability of the cell. In normal cells, p53 is kept at low 
levels by MDM2 to regulate cell growth under control (Barak et al., 1993; Wu 
et al., 1993). In response to DNA damage, or other cellular stresses, p53 is 
stabilized to modulate transcription of its effector genes (Vogelstein et al., 
2000). This induces a variety of cellular responses. The most common 
responses are cell cycle arrest allowing the cell to repair damaged DNA, and 
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apoptosis leading to the elimination of damaged cells (Oren, 2003). These 
mechanisms ensure that damaged cells are either repaired or deleted from 
the genome, thus maintaining the genetic integrity of the cell. This is why p53 
is called the guardian of the genome.  
MDM2 (mouse double minute 2) is a nuclear proto-oncogene regulated 
by p53 through a p53 binding site present in the MDM2 gene (Wu et al., 
1993). An important function of MDM2 is to regulate the expression of p53. 
MDM2 accomplishes this function in two ways: it may bind to and inhibit p53 
transcriptional activity (Momand et al., 1992), or it may promote the rapid 
degradation of p53 through the ubiquitin-dependent proteosome pathway 
(Haupt et al., 1997).  
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Figure 6. The p53 pathway 
 
 
When p53 was discovered in 1979, it was classified as an oncogene 
because of its increased expression in various human tumors. It was not until 
10 years later, when it was discovered that the originally isolated p53 was a 
mutant, that p53 was correctly characterized as a tumor suppressor gene. 
Loss of p53wt function is common in many human malignancies (~50%) 
(Caron de Fromentel and Soussi, 1992; Greenblatt et al., 1994) thus leading 
to a loss of its tumor suppressor properties. Loss of p53wt function occurs 
either via mutation or through an inhibition of its transcriptional activation 
(Vogelstein et al., 2000). In human BC, p53 mutations are less common 
(~20%) (Pharoah et al., 1999; Gasco et al., 2002). In tumors that retain p53wt, 
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like BC, p53 inactivation occurs through the deregulation and over-expression 
of MDM2 (Oliner et al., 1992; Finlay, 1993). When MDM2 is over-expressed, 
it binds to and ubiquitinates p53wt leading to its degradation by the 
proteosome. MDM2 possesses activity of an E3 ubiquitin ligase allowing it to 
target p53 for degradation. This inhibits p53wt function compromising the 
genetic stability of the cell. Loss of p53wt function induces a cascade of 
molecular changes that include CA, CIN/aneuploidy (Fukasawa et al., 1996; 
Fukasawa et al., 1997; Carroll et al., 1999) and oncogenic transformation. 
In addition to p53wt regulation, the expression of ERα has been shown 
to induce MDM2 transcription (Phelps et al., 2003). MDM2 mRNA and protein 
levels are increased in ERα+ BC tumors (Marchetti et al., 1995; Bueso-Ramos 
et al., 1996). Recently, a single nucleotide polymorphism, SNP309 T/G, was 
identified in the MDM2 promoter region that also binds ERα (Kinyamu and 
Archer, 2003; Bond et al., 2004). This SNP has been associated with 
attenuation of the p53 pathway and accelerated tumor formation in a gender-
specific and hormone-dependent manner, suggesting that hormones, like 
estrogen, may alter oncogenesis (Bond et al., 2006). 
Interrupting the p53-MDM2 interaction may presumably restore 
endogenous p53 function and be an important anti-cancer approach. Two 
small molecule inhibitors that interrupt this interaction have been reported, 
nutlins (Vassilev et al., 2004) and Reactivation of p53 and Induction of Tumor 
cell Apoptosis (RITA) (Issaeva et al., 2004). Nutlins bind to the p53-binding 
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site of MDM2 blocking the p53-MDM2 interaction. In contrast, RITA binds to 
p53 inhibiting the binding of MDM2 to p53 and its inactivation. Both molecules 
are effective as anti-tumor agents in vitro. RITA has also shown promising 
anti-tumor effects in vivo without significant adverse effects.  
  
1.8 Centrosome Amplification, Chromosomal Instability and 
Aneuploidy in Human Breast Cancer 
Genomic instability is one of the driving forces in the development and 
progression of malignant tumors. Two forms of genomic instability have been 
identified in cancer, microsatellite instability (MIN) and CIN (Boland et al., 
1998). MIN refers to gene mutations involved in DNA synthesis and repair, 
uncommon in most cancers, that essentially give rise to diploid tumors 
whereas CIN, a common characteristic of malignancy, results from the 
deregulation of the centrosome cycle leading to abnormal chromosomal 
separation and aneuploidy.  
Aneuploidy, the state of an altered chromosome number, is a 
consistent feature observed in nearly all types of cancer (Lengauer et al., 
1998). Almost a century ago, Boveri suggested that aneuploidy in cancer cells 
may occur through defects in chromosome segregation machinery (Boveri, 
1914). Boveri’s suggestion was based on his sea urchin embryo studies that 
exhibited abnormal chromosome segregation following fertilization of an egg 
with two sperm. Boveri noticed similarities between the chromosome 
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abnormalities in sea urchin embryos and those reported in cancer, these 
similarities led to his hypothesis that malignant tumors arise through 
centrosome defects that result in improper cell division. A growing body of 
evidence now supports his hypothesis.  
CIN, the rate of change in chromosome number, is the result of the 
deregulation of the normal centrosome cycle leading to CA. CA is defined as 
an increase in centrosome volume and number within a single cell, 
accumulation of excess pericentriolar material, increased microtubule 
nucleation capacity and inappropriate phosphorylation of centrosomal 
proteins (Lingle et al., 1998). A consequence of CA is the formation of 
multipolar mitotic spindles (Wang et al., 2004) leading to abnormal 
segregation of chromosomes and aneuploidy (Salisbury et al., 1999). CA 
occurs at a very early stage of cell transformation, most often resulting in 
mitotic catastrophe and eventual apoptosis. However, selection drives 
survival and proliferation of some of these cells that have acquired a growth 
advantage (Salisbury et al., 1999).  
Centrosome duplication and DNA replication are usually tightly linked 
and essential to ensure equal chromosomal segregation during cell division 
(Sluder and Hinchcliffe, 2000). In cancer, these two events may be uncoupled 
leading to CA, increased frequency of multipolar mitotic spindles and CIN 
(Lingle et al., 1998; Pihan et al., 2001; D'Assoro et al., 2002). The Aurora 
kinases play a major role in centrosome separation and maturation. All three 
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human Aurora kinases are over-expressed in many human cancers where CA 
has been observed. Because of this, the expression of the Aurora kinases, 
more specifically AurA, has become the focus as to one possible cause of CA 
(Zhou et al., 1998).  
In a study of human breast tumors, significant centrosome alterations, 
including supernumerary centrioles, excess pericentriolar material, disrupted 
centriole barrel structure, unincorporated microtubule complexes, centrioles of 
unusual length, centrioles functioning as ciliary basal bodies and 
mispositioned centrosomes, were observed (Lingle and Salisbury, 1999). 
AurA over-expression, CA, CIN and aneuploidy are defining features of 
human BC, as well as in E2-induced ACI rat mammary tumor and Syrian 
hamster kidney tumor models. These traits of human BC have been detected 
in 55-78% of human DCISs and 85-92% of human IDBCs (Makris et al., 1997; 
Arnerlov et al., 2001; Li et al., 2002a). Similarly, CA, CIN and aneuploidy have 
been reported in 84% and 91% of E2-induced rat mammary DCISs and 
primary mammary tumors (Li et al., 2002a) respectively, and in 92% of 
E2/DES-induced hamster kidney tumors (Li et al., 2001). There is growing 
evidence that these characteristics occur early and therefore, may be 
important in neoplastic transformation rather than a consequence of tumor 
progression. 
The G1/S and G2/M cell cycle checkpoints, that normally ensure the 
orderly progression of cell cycle events, can also be inactivated in cancer 
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(Hartwell and Weinert, 1989). In normal cells, DNA damage triggers 
checkpoint activation through the tumor suppressor p53 and up-regulation of 
its downstream targets. However, in some malignant tumors a p53 mutation 
has been correlated with the occurrence of CA (Weber et al., 1998; Carroll et 
al., 1999; Ouyang et al., 2001; Jeng et al., 2004; Zhu et al., 2005). In BC, 
tumors that express p53wt, as well as CA, also over-express MDM2 which 
inactivates p53wt by promoting its degradation (Carroll et al., 1999). In 
addition, the phosphorylation of p53wt by AurA at serine 315 makes it more 
susceptible to ubiquitination by MDM2 and proteolysis (Katayama et al., 
2004). Recently, it has been shown that AurA also phosphorylates p53wt at 
serine 215 which abrogates its function. This phosphorylation inhibits p53wt 
DNA binding and transcriptional activation leading to an AurA override 
causing cell cycle progression, survival and transformation (Liu et al., 2004). 
CA and CIN also develops independently of p53 mutations suggesting 
the presence of other mechanisms leading to the disruption of chromosome 
segregation. The oncogenes E6 and E7 (Duensing et al., 2000), associated 
with human papillomavirus (HPV), and mutations in BRCA1 and BRCA2 
(Deng, 2002), tumor suppressor genes associated with the development of 
familial breast and ovarian cancers, have been suggested as possible culprits 
as have cyclin E and c-myc. Deregulation of cyclin E affects processes 
involved in duplication and segregation of chromosomes leading to CIN 
(Spruck et al., 1999), and c-myc over-expression has been implicated in 
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oncogenesis by allowing accelerated passage through the G1/S checkpoint 
resulting in genomic instability (Felsher and Bishop, 1999).  
It is interesting that the over-expression of AurA and p53wt loss of 
function result in a similar cascade of CA, CIN and aneuploidy. Understanding 
these two converging pathways that lead to oncogenic transformation may 
prove to be an important step in the study of BC.  
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Chapter 2: Statement of Purpose 
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2.1 Significance 
BC is the number one diagnosed cancer in women in the United 
States. About 90-95% of all BCs are sporadic. It is evident that endogenous 
and exogenous estrogens play a crucial role in both BC causation and 
development (Bilimoria and Morrow, 1995). The role of estrogens in breast 
oncogenesis is beginning to be unraveled. Recently, AurA has been shown to 
be over-expressed in human BC (Tanaka et al., 1999). Aur kinases are part of 
a family of mitotic kinases that when aberrantly expressed may cause errors 
in mitosis that may result in the transformation of normal cells. The over-
expression of AurA has been correlated with CA, CIN and aneuploidy, all of 
which are characteristics of virtually all human solid tumors examined.  
Over the years, Li and Li have shown that E2-induced oncogenesis in 
the male Syrian hamster kidney and the female ACI rat mammary gland are 
unique animal models that mimic the molecular/cellular events reported in 
some human cancers (Li et al., 2001; Li et al., 2004). In particular, the 
morphological changes observed in the E2-induced mammary tumors of the 
ACI rat are remarkably similar to those seen in human BC. Therefore, these 
animal models are excellent tools to study the mechanisms involved in E2-
induced oncogenesis. 
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2.2 Overall Hypothesis 
The main objectives of these studies represent an attempt to 
understand the molecular and cellular events involved in solely E2-induced 
oncogenesis, using the E2-induced tumors of the kidney in the male Syrian 
hamster or the mammary gland in the female ACI rat. The main focus is to 
determine the role of the mitotic kinases AurA and B and the p53wt-MDM2 
interaction, likely contributors of CIN through CA, in estrogen oncogenesis. 
We hypothesize that E2 treatment in castrated, male Syrian hamsters 
induces oncogenesis in the kidney resulting from the over-expression 
and increased activity of AurA and B. We propose that the over-
expression of the Aur kinases leads to increased expression and 
deregulated phosphorylation of some of their centrosomal protein 
substrates, thus eliciting CA and CIN. We further propose that the loss 
of p53wt, a key tumor suppressor protein, is due to the over-expression 
of MDM2 and that by blocking the binding of MDM2 with the inhibitor, 
RITA, p53wt function will be retained. These studies will provide evidence to 
determine whether or not the over-expression of the Aur kinases is a crucial 
and early event controlling the integrity of chromosomal segregation and 
cytokinesis at cell division during E2-driven oncogenesis, and whether the 
over-expression of MDM2 leads to the loss of p53wt function during E2-
induced oncogenesis. The ultimate goal of these studies is to identify early 
molecular and cellular changes during E2-induced oncogenesis that will 
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provide new novel targets for the prevention and therapeutic intervention of 
human sporadic BC. 
 
2.3 Specific Aims Purpose 
2.3.1 Specific Aim 1. To determine the tissue localization, 
expression, activity and regulation of the mitotic kinases, AurA and B, in 
E2-induced tumors in the Syrian hamster kidney. 
The Aur kinases are essential for proper mitosis and thus, essential in 
maintaining genomic integrity. Over-expression of active AurA kinase has 
been shown to transform NIH3T3 cells, and yield tumor formation when 
implanted in nude mice, thus supporting the role of AurA as an oncoprotein 
(Bischoff et al., 1998; Zhou et al., 1998). AurA over-expression has been 
reported in a number of human solid tumors and reports indicate that it is 
over-expressed in 94% of human DCISs and in 94% of primary invasive 
breast neoplasms (Tanaka et al., 1999). While significantly less is known 
about AurB and its role in oncogenesis, it has been shown that the expression 
levels of both kinases appear to rise/decline in parallel (Keen and Taylor, 
2004).  
Previous studies in the Li laboratory have determined the localization 
and expression of AurA in E2-induced ACI rat mammary oncogenesis (Li et 
al., 2004). These studies showed an increase of AurA expression in both E2-
treated mammary glands and -induced tumors as compared to untreated 
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mammary glands at both the mRNA and protein levels. Parallel samples 
showed CA and CIN, suggesting a causal link among estrogen exposure, 
AurA over-expression, CA, CIN and aneuploidy eventually leading to 
mammary oncogenesis. 
The localization, level of expression, kinetic activity and regulation of 
AurA and B were evaluated in hamster kidneys from age-matched control 
cholesterol-treated animals, E2-treated animals and -induced tumors in the 
hamster kidney. Tissue localization was determined by 
immunohistochemistry, and the levels of protein and mRNA expression by 
Western blot analysis and real-time PCR, respectively. The kinetic activity 
was studied using an in vitro kinase assay and the estrogen regulation by an 
E2 removal/inhibition study. The data obtained from these studies provides 
data on the over-expression of AurA and B which have shown to be important 
early events in E2-induced oncogenesis leading to CA. 
 
2.3.2 Specific Aim 2. To determine the differential 
expression/phosphorylation of selected Aur kinase substrates that 
contribute to the deregulation of the centrosome cycle thus causing CA 
and CIN during E2-induced oncogenesis. 
Evidence indicates that AurA and B over-expression elicits CA leading 
to CIN and aneuploidy, all of these events are defining characteristics of 
human sporadic BC. It is likely that the over-expressed AurA and B 
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inappropriately phosphorylates centrosomal protein targets leading to CA and 
abnormalities in chromosome segregation and cytokinesis. AurA and B 
kinases are known to bind/phosphorylate a myriad of protein substrates, 
some of which have yet to be identified. It is hypothesized that when AurA 
and B are over-expressed, they may be inappropriately acting on one or more 
of their protein substrates to precipitate development of CA. 
AurA and B are known to play an important role in regulating crucial 
events during mitosis. Based on these known roles of AurA and B, we 
proposed to determine the expression level and phosphorylation of four 
known Aur substrates, centrin, histone H3, protein phosphatase 1 (PP1) and 
targeting protein for Xklp2 (TPX2). The rationale for the use of these 
substrates is as follows: Centrin: It is a ubiquitous component of the 
centrosome essential for proper centriole and centrosome duplication 
(Salisbury et al., 2002). Recently, it has been identified as an AurA substrate 
that may play a role in the ability of AurA over-expression to cause CA 
(Lukasiewicz, 2007). Histone H3:  Phosphorylation of histone H3 is required 
for proper chromosome condensation, and has been suggested to play a role 
in the interaction of the N-terminus of histone H3 and DNA (Van Hooser et al., 
1998). This role is important in facilitating CA by inappropriate or excessive 
phosphorylation, required for cell cycle progression, in the presence of AurA 
and B over-expression. PP1: It is a Ser/Thr phosphatase that can 
dephosphorylate AurA leading to its inactivation (Satinover et al., 2004). In 
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addition, active AurA can phosphorylate PP1 reducing its phosphatase 
activity (Katayama et al., 2001). TPX2:  It interacts with AurA as both an 
activator and a substrate. TPX2 is a microtubule-associated protein that 
stimulates AurA auto-phosphorylation at Thr288 and induces a change in 
AurA conformation. This conformation change protects AurA from inactivation 
from PP1 dephosphorylation. TPX2 is phosphorylated by AurA and then 
recruits AurA to the spindle microtubules (Kufer et al., 2002).  
  Most of the information on the centrosomal protein substrates of AurA 
and B originated from studies employing Xenopus, Drosophila, yeast, bacteria 
and tumor cell lines. Using the male Syrian hamster kidney and the female 
ACI rat mammary gland models, the studies proposed in this aim applied a 
molecular approach to characterize known centrosomal proteins that 
specifically interact, and are phosphorylated by AurA and B. Tissue 
localization was determined by immunohistochemistry, and the levels of 
protein expression by Western blot analysis. The estrogen regulation of some 
of these substrates was analyzed in an E2 pellet removal/inhibition study. The 
elucidation of the expression of these centrosomal proteins and 
phosphorylation by AurA and B was considered essential to assess whether 
these proteins play a crucial role in E2-induced oncogenesis. 
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2.3.3 Specific Aim 3. To determine whether p53wt function is lost 
due to the enhanced degradation induced by the over-expression of 
MDM2 during E2-induced oncogenesis, thus enhancing conditions for 
CA, CIN and oncogenic transformation.  
Loss of p53wt, an important tumor suppressor, is known to facilitate CA, 
CIN (Fukasawa et al., 1996; Fukasawa et al., 1997) and oncogenic 
transformation. Loss of p53wt function is common in many human 
malignancies. Mutations of p53wt account for about 50% of the loss observed 
(Caron de Fromentel and Soussi, 1992; Greenblatt et al., 1994). Mutations in 
p53wt are relatively uncommon in BC (15-20%) (Pharoah et al., 1999; Gasco 
et al., 2002) suggesting that loss of p53wt function is occurring by other means 
during breast oncogenesis. Two mechanisms have been proposed: 1. MDM2 
binds to p53wt resulting in its inactivation. 2. The over-expression of AurA 
leads to the phosphorylation of p53wt making it more susceptible to MDM2 
degradation (Katayama et al., 2004). 
MDM2 is an oncoprotein that acts as an E3 ubiquitin ligase targeting 
p53wt for destruction by proteosomes. Over-expressed MDM2 decreases 
p53wt levels and inhibits the DNA damage checkpoint and DNA repair. MDM2 
is over-expressed in 73% of human BCs at both the mRNA and protein levels 
(Bueso-Ramos et al., 1996).  
Interrupting the p53wt-MDM2 interaction may presumably restore 
endogenous p53wt function and be an important anti-cancer approach. A 
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small molecule inhibitor that binds to p53wt, RITA (Issaeva et al., 2004) was 
used to inhibit the binding of MDM2 to p53wt. RITA has shown promising anti-
tumor effects in vitro and in vivo without significant adverse effects. 
Protein and mRNA expression and regulation of MDM2 and p53wt were 
evaluated in hamster kidneys and mammary glands from age-matched 
control cholesterol-treated animals and E2-induced tumors. The levels of 
protein and mRNA expression were determined by Western blot analysis and 
real-time PCR, respectively. The estrogen regulation of MDM2 and p53wt was 
studied by an E2 pellet removal/inhibition study. In addition, RITAs ability to 
restore p53wt function was assessed in hamsters bearing E2-induced tumors 
in the kidney. The data obtained from these studies provides important 
information on the p53wt-MDM2 interaction during E2-induced breast 
oncogenesis. 
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Chapter 3: Materials and Methods 
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3.1 Animals and treatment  
Adult castrated male Syrian golden hamsters (LAK:LVG), outbred 
strain, weighing 90-100 g were purchased from Harlan Sprague-Dawley Inc. 
(Indianapolis, IN). They were housed in facilities certified by the American 
Association for the Accreditation of Laboratory Animal Care, acclimated for at 
least one week prior to use, maintained on a 12-hr light:12-hr dark cycle, fed 
certified rodent chow (Ralston-Purina 5002) and tap water ad libitum. The 
animal studies were carried out in adherence to the guidelines established in 
the “Guide for the Care and Use of Laboratory Animals,” (US Department of 
Health and Human Resources, NIH, 1985). Hamsters in the treatment groups 
were sc implanted with 20 mg E2 pellets as described previously (Li et al., 
1980). Age-matched control animals were implanted with 20 mg pellets of 
cholesterol. To maintain constant levels of E2, new pellets were implanted 
every 3.0 months. Their mean daily absorption was 96 ± 4 μg/day. The pellets 
were prepared by Hormone Pellet Press (Shawnee Mission, KS). Over a 6.0 
month period of E2 treatment, the average E2 concentration in serum was 
2.28 ± 0.43 ng/mL, and in the kidney was 4.57 ± 1.04 pg/mg protein (Li et al., 
1994).  
For the withdrawal studies, E2-treated hamsters for 6.0 months and 
bearing tumors were divided into four groups: 1) Maintained on E2 treatment. 
2) Withdrawn of both E2 pellets. 3) Withdrawn of the initial E2 pellet, while the 
second one remained and additionally implanted with 2 pellets of 20 mg 
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Tamoxifen citrate (Tx). 4) Control age-matched cholesterol-treated. All 
animals were killed ten days after removal of the E2 pellets and the Tx 
treatment, tumors were individually harvested from groups 1-3 and kidneys 
from group 4 for subsequent analysis. The withdrawal/treatment period was 
selected because it has been previously shown that after a 72 h E2-withdraw 
period, all estrogens are completely cleared from the circulation of E2-treated 
animals (Li et al., 1994).  
For the RITA studies, 6.0 month, E2-treated hamsters bearing tumors 
were divided into three groups. Each group was injected ip daily for 15 days 
with: 1) 0.1 mL/100 g BW vehicle. 2) 0.75 mg RITA/100 g BW. 3) 1.0 mg 
RITA/100 g BW. All animals were killed on day 16. Tumors were harvested 
for subsequent analysis. The treatment period/dose was based on a previous 
in vivo mouse study in which 1.0 mg RITA/100 g BW resulted in a decreased 
tumor volume and the inhibition of MDM2-p53wt complex formation (Issaeva 
et al., 2004).  
Intact female ACI rats were purchased from Harlan Sprague Dawley 
Inc. (Indianapolis, IN) at 6-8 weeks of age. They were housed in facilities 
certified by the American Association for the Accreditation of Laboratory 
Animal Care, acclimated for at least one week prior to use, maintained on a 
12-hr light:12-hr dark cycle, fed Teklad Rodent Diet 8604 and tap water ad 
libitum. The animal studies were carried out in adherence to the guidelines 
established in the “Guide for the Care and Use of Laboratory Animals,” (US 
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Department of Health and Human Resources, NIH, 1985). Rats in the 
treatment groups were implanted sc with 20 mg pellets containing 3 mg of E2 
plus 17 mg of cholesterol as previously described (Li et al., 2004). Age-
matched control animals were implanted with 20 mg pellets of cholesterol. 
The pellets were prepared by Hormone Pellet Press (Shawnee Mission, KS). 
Over the treatment period, the average E2 serum levels were 123.5 ± 4.8 
pg/mL (4.0 months) and 121.8 ± 3.0 pg/mL (6.0 months) (Li et al., 2002b). 
For the withdrawal studies, 6.0 month E2-treated rats bearing tumors, 
were divided into four groups: 1) Maintained on E2 treatment. 2) E2 pellet 
treatment removed. 3) Maintained on E2-treatment plus additional 
implantation of 2 pellets of 20 mg Tx. 4) Control age-matched cholesterol-
treated. All animals were killed 8 days after the removal of the E2 pellet and 
the Tx treatment. Tumors were individually harvested from groups 1-3 and 
mammary glands from group 4 for subsequent analysis. The 
withdrawal/treatment period was selected based on tumor regression studies 
performed by DiAugustine (unpublished data).  
 
3.2 Western blot 
Kidneys, mammary glands and tumors were homogenized in lysis 
buffer containing 50 mM Tris-HCl pH7.4, 0.2 M NaCl, 2 mM EDTA, 0.5% NP-
40, 50 mM NaF, 0.5 mM Na3VO4, 20 mM Na-pyrophosphate, 1 mM PMSF, 10 
µg/mL aprotinin, 10 µg/mL leupeptin, and 1 mM DTT. The supernatant 
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fractions were collected and their protein content determined with BCA 
reagents (Pierce, Rockford, IL). Proteins were separated by gel 
electrophoresis on PAGEr Gold Precast Gels (Cambrex Bio Science 
Rockland, Inc, Rockland ME) or Pierce Precise Protein Gels (Pierce) and 
transferred to a nitrocellulose membrane (PVDF membrane for Centrin). The 
following primary antibodies were used: AurA BL656 (Bethyl Labs, 
Montgomery, TX, 1:1000), AurB ab2254 (Abcam, Cambridge, MA, 1:1000), 
Centrin MCI (Salisbury, JL, Mayo Clinic, Rochester, MN, 1:25000), γ-tubulin 
MMR58 (Salisbury, JL, 1:10000), Bax 2772 (Cell Signaling Technology, 
Danvers, MA, 1:1000), histone H3 (FL-136) sc-10809 (1:1000), PP1 (E9) sc-
7482 (1:5000), TPX2 (H-300) sc-32863 (1:1000), MDM2 (SMP14) sc-965 
(1:200), p53 (Pab 240) sc-99 (1:200) and p21 (M-19) sc-471 (1:200), all from 
Santa Cruz Biotechnology, Santa Cruz, CA. The membranes were incubated 
overnight at 4oC with primary antibody followed by incubation with appropriate 
secondary antibodies for 2 hrs. Protein expression was visualized with ECL 
chemiluminescence (Amersham Biosciences, Piscataway, NJ). Densitometry 
was done using Alpha Imager 2000 (Alpha Innotech, San Leandro, CA) or 
Northern Light model B 95 (Imaging Research Inc., Ontario, Canada) and 
Scion Image software (Scion Corporation, Frederick, MD). 
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3.3 In vitro protein kinase assay 
Proteins were extracted as described for Western blotting. Aliquots, 
200 μg of total protein extracts, were incubated for 2 hrs at room temperature 
with 1 μg of AurA BL469 (Bethyl Labs) followed by a 2 hr incubation with 30 
μL Protein A/G PLUS-agarose sc-2003 (Santa Cruz Biotechnology). Normal 
IgG was used as a negative control. Immunoprecipitated complexes were 
washed several times with PBS and immediately used for kinase assays 
(Upstate, Inc., Charlottesville, VA) following the manufacturers standard 
protocol with slight modifications. Immunoprecipitates were incubated for 30 
mins at 30oC with 5X reaction buffer (40 mM MOPS, pH 7.0, 1 mM EDTA), 10 
µCi/µL of [32P]γATP (Amersham Biosciences) diluted in Upstate Mg/ATP 
cocktail. Reactions were spotted onto P81 paper, subjected to a series of 
washes in 0.75% phosphoric acid and acetone and counts per min measured 
using a scintillation counter (Beckman Coulter, Fullerton, CA).  
 
3.4 Reverse transcription PCR and quantitative real-time PCR   
Total RNA was extracted using the protocol supplied by GibcoBRL for 
Trizol Reagent (Invitrogen Corp., Carlsbad, CA). RNA integrity was evaluated 
by agarose gel electrophoresis and the RNA concentration determined by 
spectrometry.  
Reverse transcription for AurA was performed using 5 μg of total 
RNA/5 μl. First strand synthesis was performed using the manufacturer’s 
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protocol for M-MLV reverse transcriptase (Invitrogen Corp.). The reverse 
transcription reaction was performed using an iCycler thermocycler (Bio-Rad 
Laboratories, Hercules, CA). The thermocycling protocol consisted of 1 hr 
incubation at 37oC followed by 10 min incubation at 96oC. The samples were 
stored at 4oC until used for PCR analysis. 
Reverse transcription for MDM2 and p53wt was performed using 5 μg 
of total RNA/5 μl using a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA). The reaction was performed using an 
iCycler thermocycler (Bio-Rad Laboratories). The thermocycling protocol 
consisted of incubations for 10 mins at 25oC, 120 mins at 37oC followed by 5 
secs at 85oC. The samples were stored at 4oC until used for PCR analysis. 
The cDNA synthesized during the reverse transcription reaction was 
used to perform the real-time PCR reaction. For AurA, cDNA was amplified 
using the Platinum® SYBR® Green qPCR SuperMix UDG (Invitrogen Corp.) 
and gene specific primers for β-actin (FWD 5’-CAG CCG AGA GGG AAA 
TTG TG-3’; REV 5’-TCG TTG CCA ATG GTG ATG AC-3’; 101 bp amplicon)  
and AurA (FWD 5’-TGG GTG TGT GCC TCG AAA-3’; REV 5’-GAT TGA 
AGG CCG GAT GCA-3’; 102 bp amplicon) in a 7300 Real Time PCR System 
(Applied Biosystems). The thermocycling protocol consisted of incubations for 
2 mins at 50oC followed by 10 mins at 95oC. Then, the samples underwent 40 
cycles of 45 secs each at 95oC, 60oC and 72oC. The specificity of the 
amplicon was verified by running a dissociation step.  
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For MDM2 and p53wt, cDNA was amplified using Power Sybr® Green 
PCR master mix (Applied Biosystems)  and gene specific primers for β-actin 
(FWD 5’-CAG CCG AGA GGG AAA TTG TG-3’; REV 5’-TCG TTG CCA ATG 
GTG ATG AC-3’; 101 bp amplicon), MDM2 (Syrian hamster kidney - FWD 5’-
ACA GAT GTT GGA CTC TGC GTG AGA-3’; REV 5’-ATC TAA GCC TTC 
TGC CTC CAG CTT -3’; 101 bp amplicon) (ACI rat mammary gland - FWD 5’-
AGA TGT GCC TGA TGG CAA AA-3’; REV 5’-AAG TCG ACG GCT GGG 
AAT AG-3’; 128 bp amplicon) and p53wt (Syrian hamster kidney - FWD 5’-
GAA GGA AAT ATG CAT GCC GAA T-3’; REV 5’-CTC ATA GGG CAC CAC 
CAC ACT-3’; 72 bp amplicon) (ACI rat mammary gland - FWD 5’-CGA AAT 
CCT ATC CGG TCA GT-3’; REV 5’-TGA GGG CCC AAG ATA GAA TC-3’; 91 
bp amplicon)  in a 7900HT Real Time PCR System (Applied Biosystems). 
The thermocycling protocol consisted of 2 min incubation at 50oC followed by 
10 min incubation at 95oC. Then, the samples underwent 40 cycles of 45 secs 
each at 95oC, 56oC and 72oC. The specificity of the amplicon was verified by 
running a dissociation step.  
 
3.5 Immunohistochemical analysis 
Kidneys were excised, trimmed and fixed in 5% paraformaldehyde, 
followed by a rapid paraffin-embedding process. Tissue sections (6 μm) were 
prepared and dewaxed. Antigens were retrieved (Dako Target Retrieval 
Solution, Dako, Carpinteria, CA) by heating in a water bath set at 97oC for 20 
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mins or a digital decloaking chamber (Biocare Medical, Concord, CA) and 
treated with 3% H2O2 for 15 mins to block endogenous peroxidases. After 
blocking with 6% of the appropriate serum in 1% bovine serum albumin, the 
primary antibodies, AurA BL656 (Bethyl Labs, 1:1000), AurB ab2254 (Abcam, 
1:50) and TPX2 (H-300) sc-32863 (Santa Cruz Biotechnology, 1:40), were 
applied to the sections overnight at 4oC. Appropriate secondary antibodies 
were incubated for 1 hr at 25oC followed by 1 hr with Vector Laboratories Elite 
ABC (Burlingame, CA). As negative controls, similar tissue sections were 
incubated replacing the primary antibodies with the appropriate normal 
serum. The slides were counterstained with hematoxylin, dehydrated in 
alcohol and mounted in Permount medium (1:1 Permount:Xylene) before 
being examined under the microscope. 
 
3.6 Enrichment of amplified tumor centrosomes 
The isolation of amplified E2-induced tumor centrosomes was 
performed according to Moudjou and Bornens (Moudjou, 1994) with minor 
modifications. Primary tumors (8-10 g) from the kidney were minced and 
brought to 50 mL in culture medium containing 10 μl cytochalasin, 10 μl 
nocodazole and 50 μl protease inhibitor cocktail, all obtained from Sigma 
Aldrich (St. Louis, MO). The minced tumor was incubated for 30 mins at 4oC,  
washed and then resuspended in 0.1X TBS/8% sucrose containing 2 μl 
cytochalasin, 2 μl nocodazole and 10 μl protease inhibitor cocktail and 
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pressed through a stainless steel sieve and filtered through a 105 micron 
nylon mesh monofilament cloth (Small Parts, Inc., Miami Lakes, FL). The 
resulting cell suspension was lysed in a buffer containing 1 mM Tris-HCl pH 
8.0, 0.1% 2-mercaptoethanol, 0.5% Triton X-100 and 1X protease inhibitors, 
homogenized in a glass dounce and centrifuged at 2,500 x g for 10 mins. The 
lysate was placed in a 50 mL tube, under-laid with 60% sucrose and 
centrifuged at 10,000 x g for 30 mins. The upper 25 mL fraction was carefully 
aspirated, and the remaining sample was vortexed, over-laid onto a 
vegetable-dyed sucrose gradient (70%, 50% and 40% sucrose) and 
centrifuged at 40,000 x g for 1 hr. The gradient was fractionated [Fraction 
Collector and Econo Pump (Bio-Rad Laboratories) Fractionation System 
(Brandel, Gaithersburg, MD)] into 24 0.5 mL portions. The fraction volumes 
were brought to 1.5 mL with gradient buffer (10 mM PIPES pH 7.2, 0.1% 
Triton X-100 and 0.1% 2-mercaptoethanol), vortexed and centrifuged at 
50,000 x g for 1 hr. The supernatant was discarded and the pelleted fractions 
were stored at -80oC for further analysis by Western blotting.  
 
3.7 Immunofluorescence analysis 
Kidneys were excised and frozen in Tissue-Tek Cryo-OCT Compound 
(Andwin Scientific, Warner Cen, CA). Slides were fixed in absolute methanol 
for 10 mins at -20oC, blocked in 5% normal goat serum, 1% glycerol, 0.1% 
BSA, 0.1% fish skin gelatin, 0.1% triton X-100 and 0.4% sodium azide (10% 
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stock) and incubated with primary antibodies. The following primary 
antibodies Centrin 20H5 (Salisbury, JL, 1:1000), γ-tubulin (Sigma Aldrich, 
1:1000) and AurA (H-130) sc-25425 (Santz Cruz Biotechnology, 1:40) were 
applied to serial sections and incubated overnight at 25oC. Appropriate 
secondary antibodies conjugated with Alexa fluor 488 or 568 (Molecular 
Probes, Eugene, OR) were incubated for 1 hr at 25oC followed by a PBS 
wash. The slides were mounted with Pro Long Gold antifade reagent w/ DAPI 
(Invitrogen Corp.) and digital images recorded using a Zeiss Axiovert 
fluorescence microscope. 
 
3.8 Co-Immunoprecipitation  
Proteins were extracted as described for Western blotting. Aliquots, 
500 μg total protein, were incubated with primary antibody, p53 (PAb 240) 
ab26 (Abcam Inc.) at 4oC overnight. 50 μL of ImmunoPure Immobilized A/G 
beads (Pierce) were added to the proteins and incubated for an additional hr 
at 4oC. Immune complexes were washed 3 times in immunoprecipitation 
buffer A containing 190 mM NaCl, 50 mM Tris-HCl pH7.4, 6 mM EDTA and 
2.5% Triton X-100 and then 3 times in immunoprecipitation buffer B 
containing 150 mM NaCl, 10 mM Tris-HCl pH8.0, 5 mM EDTA and 0.1% 
Triton X-100. Proteins were released from immune complexes with 2-
mercaptoethanol at 99oC for 5 mins, separated by gel electrophoresis on 
Pierce Precise Protein Gels (Pierce) and transferred to nitrocellulose 
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membranes. Primary antibody against MDM2 (SMP14) sc-965 (Santa Cruz 
Biotechnology, 1:200) was incubated overnight at 4oC. Appropriate secondary 
antibody was incubated for 2 hrs and protein expression was visualized with 
ECL chemiluminescence (Amersham Biosciences). 
 
3.9 Statistical Analyses  
One way analysis of variance (ANOVA) with Tukey post-hoc tests were 
used for statistical evaluation, with the exception of the AurA kinase activity 
that was analyzed using student t test. Values were expressed as the mean ± 
SE. Statistical significance was assumed when p < 0.05. 
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Chapter 4: Experimental Results 
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4.1 Over-expression of AurA and B and CA in early E2-induced 
tumor foci of the Syrian hamster kidney 
4.1.1. AurA and B expression in early tumorous foci 
In order to assess the cellular location of AurA and B expression after 
various E2-treatment intervals (3.5-6.0 months) in early tumor foci, serial 
kidney sections were examined by H&E staining (Figure 7A) and 
immunohistochemistry. Analysis of whole kidney serial sections of 3.5-month 
E2-treated hamsters established that the expression of both AurA (Figure 7B) 
and B (Figure 7C) was confined essentially to cells present in early tumorous 
foci. AurA or B positive stained cells were not present in similar tumor foci 
sections in the absence of either primary antibody (Figure 7D). Positive 
stained AurA (Figure 7E) and B (Figure 7F) cells were also present in large 
well-established tumor foci derived from 6.0-month E2-treated hamsters, but 
not in adjacent non-involved epithelial kidney cells. 
   
4.1.2. Western blot analysis of Aur A and B in control and E2-
treated kidneys and E2-induced tumors of the kidney 
To determine the protein expression levels of AurA and B kinases, 
Western blot analysis of lysates from whole hamster kidney samples after 
3.0-, 4.0-, 5.0- and 6.0-months and primary tumors after 6.0-months of E2 
treatment was performed (Figure 8A). Only modest increases in AurA protein 
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were seen in early E2-treatment periods; however, a significant 8.7-fold rise 
was detected in primary tumors of the kidney (Figure 8B) when compared to 
control cholesterol-treated kidneys. A slower migrating AurA band, 
presumably the phosphorylated form of AurA, was observed only in E2-
induced tumors of the kidney. No detectable changes in AurB protein 
expression (Figure 8A) were observed after 3.0-5.0-months of E2 treatment. A 
slight rise in AurB expression was detected in 6.0-month E2-treated kidneys, 
and a significant 4.6-fold increase in primary E2-induced tumors of the kidney 
compared to age-matched cholesterol-treated control kidneys (Figure 8B). 
 
4.1.3. AurA mRNA expression in E2-induced tumors 
To determine whether the increased protein levels of AurA expression 
take place concurrently with similar increases in mRNA, real-time PCR 
analysis was performed in Syrian hamster E2-induced tumors of the kidney 
and those of 3.0- and 5.0-month E2-treated kidneys. A significant 6.0-fold 
increase in mRNA expression was observed in primary tumors of the kidney 
compared to age-matched cholesterol-treated control kidneys (Figure 9). 
 
4.1.4.  AurA activity in E2-induced tumors of the kidney 
To determine whether the over-expressed AurA protein in the E2-
induced tumors of the kidney was functionally active, a kinase assay was 
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performed using the synthetic construct, kemptide, as a substrate. The over-
expression of AurA led to a concomitant 2.6-fold increase in its kinase activity 
in E2-induced hamster tumors of the kidney relative to control cholesterol-
treated kidneys (Figure 10).  
 
4.1.5. Estrogen modulation of the expression of the Aur kinases 
in E2-induced tumors of the kidney 
In order to determine whether the protein expression of AurA and B 
was regulated by estrogen, Western blot analysis was performed in tumor 
samples from groups of 6.0-month tumor bearing animals continuously E2-
treated, after their E2 pellets were withdrawn or concomitantly treated with Tx 
for 10 days. The withdrawal/treatment period was selected because it has 
been previously shown that after a 72 h E2-withdraw period, all estrogens are 
completely cleared from the circulation of E2-treated animals (Li et al., 1994). 
Compared to age-matched control cholesterol-treated kidneys, an 8.0-fold 
rise in AurA expression was detected in all tumors receiving sustained E2 
treatment (Figure 11B). When compared to tumor-bearing hamsters 
continuously treated with E2, a 78% and a 79% reduction in AurA expression 
was observed after either a 10-day E2-withdrawal period or after E2 + Tx 
treatment, respectively. Likewise, E2-elicited AurB over-expression markedly 
declined after either E2-withdrawal (81%) or Tx (64%) co-administration. Cell 
proliferation, assessed by Ki-67 labeling, was not significantly altered in any 
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of the tumor groups (data not shown). The significant decline in AurA and B 
expression observed upon E2 withdrawal and E2 + Tx treatment, did not result 
in a concomitant reduction in the number/volume of amplified centrosomes. 
 
4.1.6. Western blot analysis of centrosome proteins in control 
and E2-treated kidneys and E2-induced tumors of the kidney 
Since centrin and γ-tubulin are ubiquitous centrosome protein 
components and markers associated with CA, their protein expression was 
determined in lysates of individual E2-treated hamster kidneys after 3.0-, 4.0-, 
5.0- and 6.0-months, and in primary tumors of the kidney after 6.0-months of 
treatment (Figure 12A). When compared to control cholesterol-treated 
hamster kidney samples, the centrin Western blot analysis of E2-induced 
tumor samples shows a clear shift in the centrin band from ~16 to 20 kDa. 
The upper band (~20 kDa), largely present in the tumors, may represent the 
phosphorylated form of centrin. The level of centrin expression was 
significantly increased (5.7-fold) in the tumor samples when compared to that 
observed in control cholesterol-treated animals (Figure 12B). The expression 
of γ-tubulin was nearly absent in the kidneys of both control and E2-treated 
animals, but showed a marked increase in expression, 70.0-fold, in tumor 
samples. A doublet was consistently observed in these samples (Figure 12B). 
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4.1.7.  CA in E2-induced tumorous foci of the Syrian hamster 
kidney 
In view of the fact that centrin and γ-tubulin are markers of centrosome 
number and volume, their expression was monitored in E2-induced tumor foci 
from 6.0-month E2-treated hamsters. Initially, the foci were detected in kidney 
serial sections by H&E staining (Figure 13A), and later, the amplified 
centrosomes were visualized by their positive staining for centrin and γ-
tubulin (Figure 13B-C). AurA was co-localized to the amplified centrosomes in 
the tumor focus (Figure 13C). The pattern of immunofluorescence staining of 
the centrosomal proteins in control cholesterol-treated kidneys (data not 
shown) and in 6.0-month E2-treated adjacent uninvolved kidney cells (Figure 
13D) was confined to the pair of centrioles apical to the nucleus. 
 
4.1.8. Localization of AurA and other centrosome proteins in 
isolated amplified centrosomes from E2-induced tumors of the kidney 
To determine whether AurA expression occurs concomitantly with CA, 
enriched amplified centrosome preparations of E2-induced tumors of the 
kidney were examined in 6.0- to 8.0-month E2-treated hamsters employing a 
discontinuous sucrose gradient fractionated into 24 aliquots (Figure 14). 
Western blot analysis of the aliquots established that the centrosome 
proteins, centrin and γ-tubulin, were expressed at high levels in fractions 8-
62  
10. Both proteins consistently exhibited their highest level of expression in 
fraction 9, while the intensity of their expression in other fractions was 
variable and for the most part significantly reduced. Notably, the expression of 
AurA was limited to fraction 9 confirming its distinctive association with the 
amplified tumor centrosome fraction. On the other hand, AurB expression was 
spread throughout fractions 6 to 10 (data not shown), expected of a mobile 
passenger protein. 
 
4.2 Expression of selected Aur kinase substrates in E2-induced 
tumor foci of the Syrian hamster kidney and the ACI rat mammary 
gland   
4.2.1. Tissue localization of Aur substrates in early E2-induced 
tumor foci of the kidney 
Although over 25 Aur kinase substrates have been described (Meraldi 
et al., 2004; Li and Li, 2006; Lukasiewicz, 2007), only a few commercially 
available antibodies cross react with the hamster kidney or the rat mammary 
gland. Given such limitations, centrin, histone H3, PP1 and TPX2 were 
selected to determine whether their pattern of expression follows that of 
AurA/B. Their cellular localization was assessed in serial kidney sections 
containing early tumor foci from animals treated with E2 at different time 
intervals. Sections were examined first by H&E (data not shown) and later by 
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immunohistochemistry (Figure 15A-D). Similarly to AurA, TPX2 expression 
was overwhelmingly confined to E2-induced tumor foci cells. Its level of 
expression increased along with the size of the tumor foci (Figure 15A-C). 
However, cells contained in E2-induced tumor foci, did not stain for centrin, 
histone H3 or PP1, irrespectively of the size of the foci or the length of E2 
treatment. 
 
4.2.2. Western blot analysis of Aur substrates in control and E2-
induced tumors of the kidney 
To determine whether the 8.7-fold increase in AurA protein expression 
observed in E2-induced tumors of the kidney was in tandem with similar 
increases in the expression of some of its substrates, the protein level of 
expression of non-phosphorylated and phosphorylated centrin and histone 
H3, as well as, PP1 and TPX2, was analyzed by Western blot analysis from 
control cholesterol-treated kidneys and primary tumors after 6.0-months of E2 
treatment (Figure 16A). The expression of centrin, histone H3, PP1 and TPX2 
was increased by 9.4, 11.5, 2.4 and 2.9-fold (Figure 16B), respectively, in 
primary E2-induced tumors when compared to control cholesterol-treated 
kidneys, while phospho-centrin and -histone H3 expression did not. 
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4.2.3. Estrogen modulation of the expression of Aur substrates 
non- and phosphorylated in E2-induced tumors of the kidney 
To determine whether the protein expression of non-phosphorylated 
centrin and histone H3, and their phosphorylated isoforms were regulated by 
estrogen, Western blot analysis was performed in tumor samples from groups 
of 6.0-month tumor-bearing animals that were continuously treated with E2, 
their E2 pellets withdrawn or concomitantly treated with Tx for 10 days (Figure 
17A). The expression of centrin significantly decreased 80% upon 
concomitant Tx + E2 treatment (Figure 17B). No significant changes in the 
protein expression of histone H3 and the phosphorylated forms of centrin and 
histone H3 were observed after estrogen modulation.  
  
4.2.4. Western blot analysis of Aur substrates in control and E2-
induced tumors of the mammary gland 
Similarly, to determine the protein level of expression of non- and 
phosphorylated forms of centrin and histone H3, as well as, PP1 and TPX2, 
control cholesterol-treated mammary glands and primary tumors after 6.0-
months of E2 treatment were subjected to Western blot analysis (Figure 18A). 
Expression of centrin, histone H3, PP1 and TPX2 was significantly increased 
by 2.9, 15.3, 1.8 and 2.1-fold (Figure 18B), respectively, in E2-induced 
mammary tumors when compared to control cholesterol-treated mammary 
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glands. No significant changes in the protein expression of phospho-centrin 
and -histone H3 were observed. 
 
4.2.5. Estrogen modulation of the expression of Aur substrates 
non- and phosphorylated in E2-induced tumors of the mammary gland 
In order to determine whether the protein expression of non- and 
phosphorylated forms of centrin and histone H3 were regulated by estrogen, 
Western blot analysis was performed in tumor samples from groups of 6.0-
month tumor-bearing animals continuously treated with E2, as well as in 
animals in which their E2 pellets were withdrawn or concomitantly treated with 
Tx for 8 days (Figure 19A). The expression of centrin significantly decreased 
upon E2 withdrawal or concomitant Tx + E2 treatment, 73% and 61%, 
respectively (Figure 19B). No significant changes in the protein expression of 
histone H3 and the phosphorylated forms of centrin and histone H3 were 
observed after estrogen modulation.  
 
4.2.6. Localization of Aur substrates and other centrosome 
proteins in isolated amplified centrosomes from E2-induced tumors of 
the kidney and mammary gland 
To determine whether phospho-centrin and -histone H3 expression 
occurs in parallel to CA, enriched amplified centrosome preparations of E2-
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induced tumors of the kidney and mammary gland were examined. The 
enriched centrosome fractions were obtained from 6.0- to 8.0-month treated 
hamsters (Figure 14) and from rats (data not shown) as previously described 
in section 4.1.8. Western blot analysis of the 24 fractions demonstrated that 
the expression of the phosphorylated forms of centrin and histone H3 were 
not associated with the amplified tumor centrosome fraction in either the E2-
induced tumors of the kidney or those of the mammary gland. 
 
4.3 MDM2 expression and regulation in E2-induced tumor foci of 
the Syrian hamster kidney and the ACI rat mammary gland   
4.3.1. Western blot analysis of MDM2 and p53 in control and E2-
induced tumors of the kidney 
To determine the MDM2 and p53 protein level of expression, Western 
blot analysis of lysates from control cholesterol-treated kidneys and primary 
tumors after 6.0-months of E2 treatment was performed (Figure 20A). A 
significant 8.8-fold increase in MDM2 expression was observed in primary E2-
induced tumors when compared to control cholesterol-treated kidneys (Figure 
20B). Similarly, a small, significant, 2.9-fold increase in p53 expression was 
observed in primary tumors of the kidney compared to control cholesterol-
treated kidneys (Figure 20B). 
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4.3.2. MDM2 and p53wt mRNA expression in E2-induced tumors of 
the kidney  
To determine whether E2-treatment affects the level of MDM2 and 
p53wt mRNA expression of Syrian hamster kidneys treated with E2 (3.0- and 
5.0-months) and in E2-induced tumors of the kidney, real-time PCR analysis 
was performed. No significant changes were observed in the levels of MDM2 
and p53wt mRNA expression in hamster kidneys treated with E2, however, in 
primary E2-induced tumors of the kidney, MDM2 mRNA expression exhibited 
a significant 3.5-fold increase, while p53wt levels were unchanged when 
compared to age-matched cholesterol-treated control kidneys (Figure 21).  
 
4.3.3. Estrogen modulation of MDM2 and p53 expression in E2-
induced tumors of the kidney 
In order to determine whether the protein expression of MDM2 and p53 
was regulated by estrogen, Western blot analysis was performed in tumor 
samples from groups of 6.0-month tumor bearing animals that were 
continuously E2-treated, and in similar animals in which their E2 pellets were 
withdrawn or concomitantly treated with Tx for 10 days (Figure 22A). 
Compared to age-matched control cholesterol-treated kidneys, a 13.3-fold 
rise in MDM2 expression was detected in all tumors receiving sustained E2 
treatment (Figure 22B). Upon a 10-day E2-withdrawal period, MDM2 
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expression was significantly reduced by 48% compared to that of tumors 
continuously treated with E2. Similarly, Tx co-administration resulted in a 
significant 47% decline in MDM2 expression in these tumors. In contrast, no 
change in p53 protein expression was observed after E2 pellet withdrawal or 
concomitant Tx treatment.  
 
4.3.4. Co-immunoprecipitation of MDM2 and p53wt in E2-induced 
tumors of the kidney 
To determine whether p53wt binds to MDM2 in vivo, a co-
immunoprecipitation study was performed. p53wt was immunoprecipitated 
from control cholesterol-treated kidneys and primary E2-induced kidney 
tumors and subjected to MDM2 Western blot analysis (Figure 23). A 
significant binding of p53wt to MDM2 was observed primarily in E2-induced 
tumors. 
 
4.3.5. RITA modulation of MDM2 and p53wt protein expression in 
E2-treated kidneys and E2-induced tumors of the kidney 
In order to determine whether the MDM2-p53wt interaction was 
disrupted by RITA, Western blot analysis of MDM2 and p53wt was performed 
in control cholesterol-treated kidneys and in tumor samples from groups of 
6.0-month tumor bearing animals that were continuously treated with E2 or 
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concomitantly i.p. treated with 0.75 mg or 1.0 mg RITA for 15-days. (Figure 
24A). Compared to age-matched control cholesterol-treated kidneys, an 11.7-
fold increase in MDM2 expression was detected in all tumors receiving 
sustained E2 treatment (Figure 24B). Upon concomitant RITA treatment, 
MDM2 expression was significantly increased by 13% compared to that of 
tumors continuously treated with E2. No significant increase in p53wt 
expression was detected in tumors receiving sustained E2 treatment. 
However, p53wt expression was significantly increased 64% after concomitant 
treatment with RITA compared to that of tumors continuously treated with E2 
alone.  
 
4.3.6. RITA modulation of Bax and p21 protein expression in the 
kidney 
In order to determine whether the protein expression of p53wt 
downstream targets was increased after the disruption of the MDM2-p53wt 
interaction by RITA, Western blot analysis of Bax and p21 was performed in 
control cholesterol-treated kidneys and in tumor samples from groups of 6.0-
month tumor bearing animals that were continuously treated with E2 or 
concomitantly treated with 0.75 mg or 1.0 mg RITA for 15-days (Figure 25A). 
Compared to age-matched control cholesterol-treated kidneys, a 3.4-fold 
increase in Bax expression was detected in all tumors receiving sustained E2 
treatment (Figure 25B). Upon concomitant RITA treatment, Bax expression 
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was significantly increased by 60% compared to that of tumors continuously 
treated with E2. No significant increase in p21 expression was detected in 
tumors receiving sustained E2 treatment or upon concomitant RITA treatment 
(Figure 25B).  
 
4.3.7. Western blot analysis of MDM2 and p53 in control and E2-
induced tumors of the mammary gland 
To determine the protein level of expression of MDM2 and p53, 
Western blot analysis of lysates from control cholesterol-treated mammary 
glands and primary tumors after 6.0-months of E2 treatment was performed 
(Figure 26A). A significant 7.7-fold increase in MDM2 expression was 
observed in primary tumors compared to control cholesterol-treated 
mammary glands (Figure 26B), while no significant changes in p53 protein 
expression were observed. 
 
4.3.8. MDM2 and p53wt mRNA expression in E2-induced tumors of 
the mammary gland   
Real-time PCR analysis was performed to determine the MDM2 and 
p53wt mRNA expression of ACI rat E2-induced tumors of the mammary gland 
and mammary glands treated with E2 for 3.0- and 5.0-months. MDM2 mRNA 
showed a significant 4.1-fold increase in primary tumors of the mammary 
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gland compared to age-matched cholesterol-treated control mammary glands 
(Figure 27). No significant changes in p53wt mRNA expression were observed 
in primary E2-induced tumors of the mammary gland. 
 
4.3.9. Estrogen modulation of the expression of MDM2 and p53 in 
E2-induced tumors of the mammary gland 
In order to determine whether the protein expression of MDM2 and p53 
is regulated by estrogen, Western blot analysis was performed in tumor 
samples from groups of 6.0-month tumor bearing animals that were either 
continuously E2-treated or had their E2 pellet withdrawn or concomitantly 
treated with Tx for 8 days (Figure 28A). Compared to age-matched control 
cholesterol-treated mammary glands, a 6.8-fold rise in MDM2 expression was 
detected in all tumors receiving sustained E2 treatment (Figure 28B). Upon an 
8-day E2-withdrawal period, MDM2 expression was significantly reduced by 
66% compared to that of tumors continuously treated with E2. Similarly, Tx co-
administration resulted in a significant 46% decline in MDM2 expression in 
these tumors. In contrast, no change in p53 protein expression was observed 
after E2 pellet withdrawal or concomitant Tx treatment.  
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4.3.10. Co-immunoprecipitation of MDM2 and p53wt in E2-induced 
tumors of the mammary gland 
A co-immunoprecipitation study was performed to determine whether 
p53wt binds to MDM2 in vivo. p53wt was immunoprecipitated from control 
cholesterol-treated mammary glands and primary E2-induced mammary gland 
tumors and subjected to MDM2 Western blot analysis (Figure 29). As in the 
E2-induced tumors of the kidney, p53wt binds to MDM2 in E2-induced 
mammary tumors.
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Figure 7. Immunostaining of AurA and B in Syrian hamster E2-
induced early tumor foci of the kidney 
Representative kidney serial sections from 3.5-month treated hamster 
kidneys: A. H&E staining showing a small tumor focus. The cells present in 
the tumor foci were AurA (B) and B (C) positive. D. A negative control kidney 
serial section without primary antibodies. Representative kidney serial 
sections from 6-month treated hamster kidneys: AurA (E) and B (F) positive 
stained cells were confined to the E2-induced tumor foci. Magnification: 40X. 
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Figure 8. Effect of estrogen treatment on the protein expression of 
AurA and B in the Syrian hamster kidney 
A. No significant changes in the expression of AurA were observed in either 
cholesterol-treated control (C) or in E2-treated kidney samples after 3 (E3), 4 
(E4) and 5-months (E5) E2-treatment. After 6 months of E2 treatment (E6), 
there was a slight increase in AurA expression followed by a marked rise in 
E2-induced tumors (T). A doublet was present in the tumor samples which 
may represent the native and phosphorylated forms of AurA. AurB expression 
was detected only in T samples. GAPDH was used as a loading control. B. In 
T samples, the expression of AurA and B were significantly increased, 8.7- 
and 4.6-fold, respectively, as compared to C kidney samples. Data represent 
the mean ± SE, n=6. Statistical significance was determined by one way 
ANOVA with a Tukey post hoc test, ** p < 0.001 vs C. 
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Figure 9. Effect of estrogen treatment in the mRNA expression of 
AurA by real-time PCR in the Syrian hamster kidney 
AurA mRNA levels were analyzed by real-time PCR from Syrian hamster 
kidneys treated with cholesterol (C), E2 for 3 (E3) or 5 (E5) months and E2-
induced kidney tumors (T). A significant 6.0-fold increase was detected in T 
samples compared to C samples. Data represent the mean ± SE, n=6. 
Statistical significance was determined by one way ANOVA with a Tukey post 
hoc test, ** p < 0.001 vs C, E3 and E5. 
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Figure 10. Effect of estrogen treatment on AurA kinase activity in the 
Syrian hamster kidney and in E2-induced tumors of the kidney 
A significant 2.6-fold increase in AurA kinase activity was observed in E2-
induced hamster tumors of the kidney (T) when compared to cholesterol-
treated control (C) hamster kidneys, t-test, * p < 0.05 vs C, n=6.
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Figure 11. Estrogen modulation of Aur kinase protein expression in 
the Syrian hamster E2-induced tumors of the kidney 
A. A significant decline in AurA and B expression was observed after the E2 
10-day withdrawal period (T-Eout), 78 and 81% respectively, and after 
concomitant treatment with Tx (T-tam), 79 and 64% respectively (B). GAPDH 
was used as a loading control. Data represent the mean ± SE, n=3/group. 
Statistical significance was determined by one way ANOVA with a Tukey post 
hoc test, ** p < 0.001 vs C, ♠ p < 0.05 vs T. 
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Figure 12. Effect of estrogen treatment in the protein expression of 
centrin and γ-tubulin in the Syrian hamster kidney and in E2-induced 
tumors of the kidney 
A. A clear shift in the centrin band was observed among control cholesterol-
treated (C) and E2-treated kidneys for 3 (E3), 4 (E4), 5 (E5) or 6 (E6) months 
and in E2-induced tumor samples (T). The tumor upper band present may 
represent the phosphorylated form of centrin. γ-tubulin expression was very 
low in both C and in E2-treated animals, but showed a marked increase in 
expression in the T samples. A doublet was consistently observed in these 
samples. GAPDH was used as a loading control. B. T samples showed a 
significant 5.7-fold increase in centrin and a 70.0-fold increase in γ-tubulin 
expression when compared to C samples. Data represent the mean ± SE, 
n=3/group. Statistical significance was determined by one way ANOVA with a 
Tukey post hoc test, ** p < 0.001 vs C. 
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Figure 13. Effect of E2 in centrosome number and size in Syrian 
hamster tumor foci of the kidney 
Centrosomes and nuclei were observed by fluorescent microscopy of serial 
sections labeled with antibodies against centrin 20H5, γ-tubulin, AurA and 
DAPI (blue) (B-D) following a corresponding 6-month E2-induced tumor foci 
area stained for H&E (A). In the tumor foci, centrosome amplification in size 
and number was evident (B). AurA co-localizes to the amplified centrosomes 
(C). Numerous centrosomes were much larger and often more numerous 
than those centrosomes in adjacent, uninvolved tissue (D). 
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Figure 14. Localization of AurA and centrosome proteins, γ-tubulin 
and centrin, to isolated centrosome fractions of Syrian hamster E2-
induced tumors of the kidney 
Centrosome isolation fractions from a combined sample of E2-induced kidney 
tumors depicting the presence of AurA, γ-tubulin and centrin. Note that the 
AurA expression peak is located in fraction 9, where a major peak for γ-
tubulin and centrin expression is also present.
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Figure 15. Effect of estrogen treatment on the protein expression of 
TPX2 in Syrian hamster tumor foci of the kidney 
The number of positive cells stained for TPX2 increased upon estrogen 
treatment. A. A small tumor focus from a 4.0-month E2-treated kidney. B. An 
intermediate tumor focus from a 6.0-month E2-treated kidney. C. A large 
tumor focus from a 6.0-month E2-treated kidney. D. Kidney serial section 
without primary antibody. 
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Figure 16. Protein expression of centrin, histone H3, PP1 and TPX2 in 
Syrian hamster E2-induced tumors of the kidney 
Western blot analysis (A) revealed that the expression of centrin, histone H3, 
PP1 and TPX2 expression was markedly increased (B), 9.4, 11.5, 2.4 and 
2.9-fold, respectively, in E2-induced tumors (T) when compared to control 
cholesterol-treated samples (C). GAPDH was used as a loading control. Data 
represent the mean ± SE, n=3. Statistical significance was determined by one 
way ANOVA with a Tukey post hoc test, ** p < 0.001 vs C, * p < 0.05 vs C. 
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Figure 17. Estrogen modulation of the protein expression of centrin 
and histone H3 in Syrian hamster E2-induced tumors of the kidney 
A. The protein expression of centrin and histone H3 was determined in 6-
month age-matched kidney samples from control cholesterol-treated animals 
(C) and in tumors from animals continuously treated with E2 (T), after a 10-
day E2 withdrawal (T-Eout) and after a 10-day concomitant Tx (T-tam) 
treatment period. B. A significant 80% decline in centrin expression was 
observed after 10-day concomitant treatment with Tx. No significant changes 
in histone H3 protein expression were observed after estrogen modulation. 
GAPDH was used as a loading control. Data represent the mean ± SE, 
n=3/group. Statistical significance was determined by one way ANOVA with a 
Tukey post hoc test, * p < 0.05 vs C, ♠ p < 0.05 vs T. 
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Figure 18. Protein expression of centrin, histone H3, PP1 and TPX2 in 
ACI rat mammary glands and in E2-induced mammary tumors 
A. The expression of centrin, histone H3, PP1 and TPX2 was significantly 
increased, 2.9, 15.3, 1.8 and 2.1-fold, respectively, in E2-induced tumors (T) 
when compared to control cholesterol-treated (C) samples (B). β-actin was 
used as a loading control. Data represent the mean ± SE, n=3. Statistical 
significance was determined by one way ANOVA with a Tukey post hoc test, * 
p < 0.05 vs C. 
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Figure 19. Estrogen modulation of the protein expression of centrin 
and histone H3 in ACI rat mammary glands and in E2-induced mammary 
tumors 
A. The expression of centrin and histone H3 was determined after 6-month 
cholesterol-treatment (C) and in E2-induced tumors from animals continuously 
treated with E2 (T), after an 8-day E2-withdrawal period (T-Eout) and after an 
8-day concomitant Tx treatment (T-tam). β-actin was used as a loading 
control. A significant decline in centrin expression was observed after either 
an 8-day E2-withdrawal period or after 8-days of concomitant Tx treatment, 
73% and 61%, respectively (B). No significant changes in histone H3 protein 
expression were observed after estrogen modulation. Β-actin was used as a 
loading control. Data represent the mean ± SE, n=3/group. Statistical 
significance was determined by one way ANOVA with a Tukey post hoc test, 
** p < 0.001 vs C, * p < 0.05 vs C, ♠ p < 0.05 vs T. 
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Figure 20. Effect of estrogen treatment in the protein expression of 
MDM2 and p53 in the Syrian hamster kidney and in E2-induced tumors of 
the kidney 
A. The expression of MDM2 was low in samples from cholesterol-treated 
controls (C), however, MDM2 and p53 expression was significantly increased, 
8.8- and 2.9-fold, respectively, in E2-induced tumors (T) when compared to C 
samples (B). GAPDH was used as a loading control. Data represent the 
mean ± SE, n=6. Statistical significance was determined by one way ANOVA 
with a Tukey post hoc test, ** p < 0.001 vs C.
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Figure 21. Effect of E2 in the mRNA expression of MDM2 and p53wt, 
measured by real-time PCR, in the Syrian hamster kidney 
In E2-induced tumors of the kidney (T), a significant 3.5-fold increase in 
mRNA MDM2 expression was detected, but no significant changes were 
observed in p53wt expression when compared to cholesterol-treated control 
samples (C). In addition, no significant changes in the expression of MDM2 or 
p53wt were observed in either 3- (E3) or 5-month (E5) E2-treated kidney 
samples. Data represent the mean ± SE, n=6. Statistical significance was 
determined by one way ANOVA with a Tukey post hoc test, * p < 0.05 vs C, 
E3 and E5. 
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Figure 22. Estrogen modulation of the protein expression of MDM2 
and p53 in Syrian hamster E2-induced tumors of the kidney 
A. A significant decline, 48 and 47%, in MDM2 protein expression was 
observed in E2-induced tumors of the kidney after a 10-day withdrawal period 
of E2 (T-Eout) and after concomitant treatment with Tx (T-tam), respectively 
(B). No significant changes in p53 protein expression were observed after 
estrogen modulation. GAPDH was used as a loading control. Data represent 
the mean ± SE, n=3/group. Statistical significance was determined by one 
way ANOVA with a Tukey post hoc test, ** p < 0.001 vs C, ♠ p < 0.05 vs T.
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Figure 23. Binding of p53wt and MDM2 in Syrian hamster kidneys and 
in E2-induced tumors of the kidney 
p53wt was immunoprecipitated from Syrian hamster kidneys treated with 
cholesterol (HKC) and E2-induced kidney tumors (HKT) and subjected to 
Western blot analysis for the presence of MDM2. 
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Figure 24. Effect of the MDM2 inhibitor RITA on the protein expression 
of MDM2 and p53 in Syrian hamster kidneys and in E2-induced tumors of 
the kidney 
A. A significant increase in MDM2 and p53 expression, 13 and 64%, 
respectively (B), was observed after a 15-day concomitant treatment period 
with 0.75 mg (T+0.75mg RITA) or 1.0 mg RITA (T+1.0mg RITA). GAPDH was 
used as a loading control. Data represent the mean ± SE, n=4. Statistical 
significance was determined by one way ANOVA with a Tukey post hoc test, 
*p < 0.05 vs C, ♦p < 0.05 vs T.  
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Figure 25. Effect of the MDM2 inhibitor RITA on the protein expression 
of Bax and p21 in Syrian hamster kidneys and in E2-induced tumors of 
the kidney  
A. A significant increase in the expression of Bax, 60% (B), was observed 
after a 15-day concomitant treatment of 0.75 mg (T+0.75mg RITA) or 1.0 mg 
RITA (T+1.0mg RITA). No significant increase in p21 expression was 
observed after concomitant RITA treatment. GAPDH was used as a loading 
control. Data represent the mean ± SE, n=4. Statistical significance was 
determined by one way ANOVA with a Tukey post hoc test, *p < 0.05 vs C, ♦p 
< 0.05 vs T.  
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Figure 26. Protein expression of MDM2 and p53 in ACI rat mammary 
glands and in E2-induced mammary tumors 
MDM2 expression was markedly increased, 7.7-fold (B), in E2-induced tumors 
(T), when compared to control cholesterol-treated mammary gland samples 
(C), while p53 expression was very low and only detected in T samples. β-
actin was used as a loading control. Data represent the mean ± SE, n=6. 
Statistical significance was determined by one way ANOVA with a Tukey post 
hoc test, * p < 0.05 vs C.
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Figure 27. mRNA expression of MDM2 and p53wt, measured by real-
time PCR, in ACI rat mammary glands and E2-induced mammary tumors 
A significant 4.1-fold increase in MDM2 mRNA expression was detected in 
E2-induced tumor samples (T) compared with cholesterol-treated control 
samples (C), while no significant changes were detected in p53wt. In addition, 
no significant changes in the expression of MDM2 or p53wt were observed in 
either 3- (E3) or 5-month (E5) E2-treated kidney samples. Data represent the 
mean ± SE, n=6. Statistical significance was determined by one way ANOVA 
with a Tukey post hoc test, ** p < 0.001 vs C, E3 and E5. 
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Figure 28. Estrogen modulation of MDM2 and p53 protein expression 
in ACI rat mammary glands and in E2-induced mammary tumors 
A. A significant decline, 66 and 46%, respectively (B), in MDM2 expression 
was observed in E2-induced mammary tumors after an 8-day withdrawal 
period of E2 (T-Eout) and after concomitant treatment with Tx (T-tam). No 
significant changes in p53 protein expression were observed after estrogen 
modulation. β-actin was used as a loading control. Data represent the mean ± 
SE, n=3/group. Statistical significance was determined by one way ANOVA 
with a Tukey post hoc test, * p < 0.05 vs C, ♠ p < 0.05 vs T. 
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Figure 29. p53wt and MDM2 binding in ACI rat mammary glands and in 
E2-induced mammary tumors 
p53wt was immunoprecipitated from ACI rat mammary glands treated with 
cholesterol (MGC) and from E2-induced mammary gland tumors (MGT) and 
subjected to Western blot analysis for the presence of MDM2.
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Chapter 5: Discussion 
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5.1 General Discussion 
CIN and aneuploidy are defining features of human sporadic BC. 
Almost a century ago, Boveri proposed that aneuploidy in cancer cells may 
arise through errors in chromosome segregation due to centrosome defects 
(Boveri, 1914). CA has been correlated with CIN and aneuploidy as defining 
features of human BC (Makris et al., 1997; Lingle et al., 1998; Arnerlov et al., 
2001) as well as in E2-induced tumors of the ACI rat mammary gland (Li et al., 
2002a; Li et al., 2004) and the Syrian hamster tumors of the kidney (Li and Li, 
2003; Hontz et al., 2007). Additionally, these defining features of estrogen-
induced oncogenesis have been causally linked to the over-expression of the 
mitotic kinase, AurA in human BC (Katayama et al., 2003) and in E2-induced 
tumors (Li et al., 2004; Hontz et al., 2007). 
The G1/S and G2/M checkpoints act through the tumor suppressor p53 
to ensure the orderly progression of the cell cycle. In some malignant tumors 
a p53wt mutation has been correlated with CA (Weber et al., 1998; Carroll et 
al., 1999; Ouyang et al., 2001; Jeng et al., 2004; Zhu et al., 2005). In BC 
tumors that retain p53wt, MDM2 over-expression is often observed in 
synchrony with CA (Carroll et al., 1999). MDM2 over-expression results in the 
degradation of p53wt and the loss of function which is enhanced by its 
phosphorylation by AurA (Katayama et al., 2004).  
For the first time, in the current study, the data demonstrate a link 
between the estrogen-induced over-expression of the oncoproteins AurA and 
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MDM2 and the molecular cascade of CA, CIN and aneuploidy observed in the 
E2-induced Syrian hamster tumors of the kidney. Based on these results and 
similar previous reports in both human BC and the ACI rat, a correlative 
sequence of events is proposed for E2-induced oncogenesis beginning with 
E2 interacting with its receptor, ERα, leading to the subsequent over-
expression of AurA and MDM2, CA, CIN, aneuploidy and eventual neoplastic 
transformation (Figure 30). These early molecular and cellular changes during 
E2-induced oncogenesis may provide new novel targets for the prevention 
and therapeutic intervention of human sporadic BC. 
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Figure 30. Schematic representation of the proposed pathway of 
events leading to neoplastic transformation during E2-induced 
oncogenesis  
E2, acting through ERα, results in the sustained over-expression of AurA and 
MDM2. Over-expressed AurA leads to CA through the deregulated 
phosphorylation of its centrosomal protein substrates. Over-expressed MDM2 
leads to CA through the loss of function of p53wt. Loss of function of p53wt can 
be enhanced by AurA phosphorylation of p53wt. CA leads to the development 
of CIN, aneuploidy and eventual BC. 
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5.2 Overall Conclusions 
AurA and B expression 
The Auroras are a family of mitotic kinases essential for the proper 
execution of various mitotic events including: centrosome duplication, 
maturation and separation, spindle assembly and stability, chromosome 
duplication and segregation and cytokinesis (Carmena and Earnshaw, 2003; 
Katayama et al., 2003).  
The over-expression of AurA and B in the early tumor foci of the Syrian 
hamster kidney is in agreement with previously published reports showing 
AurA over-expression in E2-induced tumors of the ACI rat mammary gland (Li 
et al., 2004) and in human BC (~94%) (Tanaka et al., 1999). The over-
expressed AurA in the E2-induced tumors shows the presence of a doublet 
which may represent the native and phosphorylated forms of AurA.  
IHC analysis of these E2-induced tumors showed that their expression 
was confined to cells present in tumor foci. Positively stained cells were 
observed as early as 3.5 months of E2 treatment suggesting that the AurA 
and B over-expression is an early event, that can only be observed by IHC, 
as these small early foci are probably diluted during the processing of whole 
tissue lysates for Western blot anaylsis.  
CA, monitored by the over-expression of centrin and γ-tubulin, was 
observed in concert with AurA and B over-expression in E2-induced tumors of 
the Syrian hamster kidney, as well as in similarly induced tumors of the ACI 
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rat mammary gland (Li et al., 2004). In the hamster kidney model, the over-
expressed centrin showed a clear shift in the centrin band between 
cholesterol-treated control and E2-treated animals and E2-induced tumor 
samples. A doublet was also present in γ-tubulin expression E2-induced 
tumors of the kidney similar to differential phosphorylation states reported in 
E2-induced ACI rat mammary gland tumors (Li et al., 2004) and non-
mammalian species (Oakley and Oakley, 1989; Lajoie-Mazenc et al., 1996). 
AurA expression was associated with an amplified tumor centrosome fraction 
isolated from a combined sample of E2-induced tumors of the kidney. 
Additionally, AurA co-localized to amplified centrosomes in E2-induced tumor 
foci as identified by immunofluorescence. The over-expression of the Aur 
kinases, specifically AurA, is consistent with the postulation of its involvement 
in eliciting CA (Zhou et al., 1998).  
The discovery that AurA and B are persistently over-expressed in early 
tumorous foci of the kidney and AurA in mammary dysplasias and DCIS in 
female ACI rats (Li et al., 2004), both induced by E2, suggests that these 
kinases may be under direct or indirect estrogen control. This is now 
supported by our finding that AurA protein expression showed a marked 
decline in tumors upon E2 withdrawal or after the co-administration of Tx in 
the presence of E2 as compared with corresponding tumors maintained on E2 
alone. The relatively brief period of E2 withdrawal or E2 plus Tx co-
administration did not result in a decrease of CA. This result was not 
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unexpected as centrosomes are complex structures, containing the relatively 
stable proteins centrin and γ-tubulin, which likely require many cell cycles to 
be depleted from the centrosome structure. 
In the hamster kidney model, AurA mRNA was over-expressed 6.0-fold 
in E2-induced tumors of the kidney compared with age-matched cholesterol-
treated control kidneys. These data are consistent with elevated AurA mRNA 
levels reported in E2-induced tumors of the ACI rat (Li et al., 2004) and 
human BC (~62%) (Miyoshi et al., 2001). In addition, over-expressed AurA 
led to a concomitant increase in AurA kinase activity in E2-induced tumors of 
the kidney compared with age-matched cholesterol-treated control kidneys. 
The over-expression of active AurA kinase has the ability to transform 
NIH3T3 cells and induce tumor formation when implanted in nude mice, thus 
supporting the role of AurA as an oncoprotein (Bischoff et al., 1998; Zhou et 
al., 1998).  
Persistant over-expression of AurA and B has been associated with 
CA, CIN and aneuploidy (Carmena and Earnshaw, 2003; Katayama et al., 
2003; Li et al., 2004; Fu et al., 2007), key molecular changes observed during 
oncogenesis. Previous work in our lab has established CIN and aneuploidy as 
early events in solely E2-induced tumors of the hamster kidney (Li et al., 1999; 
Li et al., 2001; Papa et al., 2003), and in the E2-induced ACI rat mammary 
tumor model. These traits have been detected in 55-78% of human DCISs 
and 85-92% of human IDBCs (Makris et al., 1997; Arnerlov et al., 2001; Li et 
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al., 2002a). Similarly, CA, CIN and aneuploidy have been reported in 84% 
and 91% of E2-induced rat mammary DCISs and primary mammary tumors 
(Li et al., 2002a), respectively. While the precise relationship between 
sustained AurA and B over-expression and CA leading to CIN and aneuploidy 
has yet to be defined, there is growing correlative evidence that these 
characteristics occur early and therefore, may be important molecular 
alterations representing a common early pathway in E2-driven neoplastic 
transformation, rather than a consequence of tumor progression.  
 
Aur kinase substrates 
CA, detected in nearly all cancers, has long been implicated as a 
cause of CIN and aneuploidy leading to neoplastic transformation (Boveri, 
1914; Lingle et al., 1998; Pihan et al., 2001). However, the mechanism by 
which CA occurs is not well understood. The two prevailing views are that CA 
arises from either cell division failure or a disruption of the centriole 
duplication cycle (Nigg, 2002; Duensing et al., 2007). In combination, AurA 
and B phosphorylate more than 25 currently known centrosomal and mitotic 
protein substrates (Li and Li, 2006). The phosphorylation of any individual or 
combination of these substrates might affect the deregulation of the 
centrosome cycle leading to CA and downstream molecular changes leading 
to tumor formation. The data show that four of these Aur substrates, centrin, 
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histone H3, PP1 and TPX2, are over-expressed in the Syrian hamster tumor 
foci of the kidney and the ACI rat mammary gland.  
Centrin is a calcium binding protein that is required for centriole 
duplication and is one of the first proteins to localize at sites of newly forming 
centrioles (Salisbury, 2007). Centrin and AurA expression overlap throughout 
the cell cycle and in vitro kinase assays demonstrated the ability of AurA to 
phosphorylate centrin (Lukasiewicz, 2007). In addition, over-expression of 
AurA in HeLa cells led to increased levels of phospho-centrin suggesting that 
this phosphorylation has a stabilizing effect on the expression of centrin 
(Lukasiewicz, 2007). Therefore, we can speculate that the over-expression of 
centrin we are observing may be due to phosphorylation by AurA. This 
stabilizing phosphorylation may be contributing to the CA observed in the 
Syrian hamster tumors of the kidney and ACI rat mammary gland by 
interfering with proper centriole/centrosome duplication.  
Chromatin condensation is essential for cell division in eukaryotes. 
Phosphorylation of histone H3 is considered to be a crucial event required for 
chromatin condensation and cell cycle progression (Hans and Dimitrov, 
2001). Studies indicate that both AurA and B have the ability to effectively 
phosphorylate histone H3 at Ser-10 in vitro and in vivo (Crosio et al., 2002). 
The over-expression of the Aur kinases may be leading to the constituitive 
phosphorylation of histone H3 and accelerated progression through the cell 
cycle thus increasing proliferation, as reported for hepatocellular carcinoma 
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(Sistayanarain et al., 2006). The link between increased histone H3 
phosphorylation and CA remains elusive. The stages of centrosome 
duplication are tightly linked with the cell cycle. Therefore, one effect of cell 
cycle deregulation, via the over-expression of histone H3, could be the 
accumulation of centrosome defects in the cell and eventual CA.  
The current results showed that both centrin and histone H3 were 
over-expressed at the protein level in E2-induced Syrian hamster tumors of 
the kidney and the ACI rat mammary gland, however, we were unable to 
determine the differential expression of phospho-centrin and -histone H3 
during E2-induced oncogenesis due to the use of unstable and unpredictable 
phospho-antibodies. Additionally, our attempts to localize phospho-centrin 
and -histone H3 in isolated amplified tumor centrosomes were unsuccessful, 
presumably due to the lack of reliable phospho-antibodies. Nevertheless, we 
were able to show a decline in centrin protein expression in tumors upon E2 
withdrawal or the co-administration of Tx in the presence of E2 as compared 
with corresponding tumors maintained on E2 alone, suggesting that centrin is 
under direct or indirect estrogen control. In contrast, we observed no 
significant changes in histone H3 protein expression upon E2 withdrawal or 
the co-administration of Tx in the presence of E2 as compared with 
corresponding tumors maintained on E2 alone.  
Further, we examined the expression of PP1 and TPX2, proteins that 
interact with AurA as both regulators and substrates. Their roles in the 
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regulation of AurA have been well defined with TPX2 as an activator (Eyers 
and Maller, 2004) and PP1 as an inhibitor of AurA kinase activity (Satinover et 
al., 2004). The roles of PP1 and TPX2 as substrates of AurA are not as clear. 
Upon phosphorylation by AurA, the phosphatase activity of PP1 is reduced 
(Katayama et al., 2001) and TPX2 is believed to play a crucial role in the 
localization of AurA to the spindle microtubules (Kufer et al., 2002). TPX2 is 
required for spindle pole formation, and it has been reported that altering 
TPX2, either by depletion or over-expression, leads to a failure in spindle 
assembly (Gruss et al., 2002). 
The results show that both PP1 and TPX2 show an increase in protein 
expression in E2-induced tumors of the Syrian hamster kidney and the ACI rat 
mammary gland. The importance of these results, while interesting, remains 
unclear in the absence of phospho-antibody data. In addition, TPX2 primarily 
localizes to the cells in the tumor foci. The localization of TPX2, shortly after 
4.0-months of E2 treatment, suggests its involvement during early stages of 
tumor development.  
These results, while preliminary, suggest that these four Aur substrates 
may prove to be important players in eliciting the alterations observed during 
early stages of E2-induced oncogenesis. However, the roles of these 
substrates will only be clearly defined when improved and stable phospho-
antibodies are developed. Thus, the significance of the over-expression of 
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these Aur substrates during E2-induced oncogenesis, and their role in CA and 
eventual neoplastic transformation remains elusive. 
 
MDM2-p53 
The G1/S and G2/M cell cycle checkpoints, that normally ensure the 
orderly progression of cell cycle events, can be inactivated during 
oncogenesis (Hartwell and Weinert, 1989). In normal cells, DNA damage 
triggers checkpoint activation through the tumor suppressor p53 and up-
regulation of its downstream targets. Mutations in p53 are common in many 
human tumors (~50%) (Caron de Fromentel and Soussi, 1992; Greenblatt et 
al., 1994) leading to a loss of its tumor suppressor properties. However, p53 
mutations in BC are less common (~20%) (Pharoah et al., 1999; Gasco et al., 
2002; Lacroix et al., 2006). In tumors that retain p53wt, like BC, p53 
inactivation occurs mainly through the deregulation and over-expression of 
MDM2 (Oliner et al., 1992; Finlay, 1993). Our results show a marked increase 
in MDM2 protein and mRNA expression in E2-induced Syrian hamster tumors 
of the kidney and in ACI rat mammary gland tumors, providing additional 
evidence that the inactivation of p53wt through MDM2 over-expression may be 
a common pathway in estrogen-driven oncogenesis.  
MDM2 is regulated by p53 through a p53 binding site present in the 
MDM2 gene (Wu et al., 1993). In addition to p53 regulation, the expression of 
ERα has been shown to induce MDM2 transcription (Phelps et al., 2003). In 
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ERα+ BC tumors, MDM2 gene amplification is uncommon, although MDM2 
mRNA and protein levels are often increased, 73 and 71%, respectively 
(Marchetti et al., 1995; Bueso-Ramos et al., 1996; Turbin et al., 2006). 
Additionally, in MCF-7 cells, mitogen stimulation, such as E2, induced 
elevated expression of MDM2 (D'Assoro et al., 2008). These results suggest 
that MDM2 expression is under estrogen direct or indirect control as 
supported by our finding that upon E2 withdrawal or the co-administration of 
Tx in the presence of E2, MDM2 protein expression was markedly decreased 
in these tumors as compared with tumors maintained on E2 alone.  
Binding studies of MDM2 oncoprotein and p53 provided evidence that 
the bound p53 is wild type and not mutated in E2-induced Syrian hamster 
tumors of the kidney and in the ACI rat mammary gland. The binding of over-
expressed MDM2 oncoprotein to p53wt facilitates the degradation of p53wt via 
ubiquitin ligase and the proteasome, contributing to the CA, CIN and 
aneuploidy seen in E2-induced Syrian hamster tumors of the kidney and the 
ACI rat breast. Human breast DCISs exhibit a high frequency of CA (Lingle et 
al., 1998; Carroll et al., 1999; Lingle et al., 2002). In tumors that retain p53wt, 
high levels of MDM2 were also observed (Carroll et al., 1999). Similarly, over-
expression of MDM2 in Swiss 3T3 cells (Carroll et al., 1999) and E2 
stimulation of MDM2 expression in MCF-7 cells (p53wt) (D'Assoro et al., 2008) 
resulted in CA and CIN. These results suggest that MDM2 over-expression, 
resulting in a loss of p53wt, commonly results in CA. 
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In addition, the phosphorylation of p53wt by the oncoprotein AurA at 
serine 315 makes it more susceptible to ubiquitination by MDM2 and 
proteolysis (Katayama et al., 2004). AurA also phosphorylates p53wt at serine 
215 which abrogates its function. This phosphorylation inhibits p53wt DNA 
binding and transcriptional activation leading to an AurA override causing cell 
cycle progression, survival and transformation (Liu et al., 2004). Previously, 
we have shown over-expression of AurA and its link to CA, CIN and 
aneuploidy in the E2-induced Syrian hamster tumors of the kidney (Hontz et 
al., 2007) and the ACI rat mammary gland (Li et al., 2004). Interestingly, both 
the over-expression of AurA and loss of p53wt function via MDM2 over-
expression lead to a similar molecular cascade of CA, CIN and aneuploidy.  
Disrupting the MDM2-p53wt interaction during oncogenesis is of vital 
importance for reactivating p53wt and restoring its tumor suppressor function. 
The small molecule inhibitor RITA prevents the MDM2-p53 interaction in vitro 
and in vivo and displays anti-tumor activity without significant adverse effects 
(Issaeva et al., 2004). RITA functions by binding to p53, inhibiting the MDM2-
p53 binding leading to p53 inactivation. Treatment of tumor-bearing animals 
with RITA led to a significant increase in p53wt and a corresponding increase 
in p53 downstream targets, MDM2 and Bax. In contrast, no significant 
changes were observed in p21 protein expression after RITA treatment. 
Previous reports show that treatment with RITA correlates with increased 
expression of MDM2 in a p53wt dependent manner (Issaeva et al., 2004). 
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Additionally, p53 restoration in murine leukemia cells lacking p53 led to a 
correlated increase in Bax mRNA and protein levels (Miyashita et al., 1994a; 
Miyashita et al., 1994b; Selvakumaran et al., 1994). While Bax leads to 
apoptosis and a cytotoxic cell response, p21 leads to cell cycle arrest and a 
cytostatic cell response. Previous studies showed a decreased binding of p53 
to p300 which can activate p53 by acetylation (Issaeva et al., 2004). 
Additionally, previous studies in HCT116 cells show that disruption of the p53-
p300 interaction leads to a failure of p21 activation which then favors 
apoptosis over cell cycle arrest (Iyer et al., 2004). Our results suggest that 
RITA is leading to an apoptotic response in the damaged tumor cells via p53 
stimulation of Bax. Therefore, previous RITA studies, which showed an 
induction of apoptosis mediated by p53wt using TUNEL assays (Issaeva et al., 
2004), are in support of our current findings. 
Our findings suggest that RITA can directly inhibit the MDM2 mediated 
inactivation of p53wt observed during estrogen-induced oncogenesis. If used 
as an early intervention, before significant oncoprotein and chromosomal 
changes, RITA may maintain p53wt function, thus potentially inhibiting CA, 
CIN and transformation.  
 
5.3 Future Directions 
Future directions should include further study of the regulation of AurA 
and MDM2 by estrogens, the study of Aur kinase substrates as better 
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antibodies, both non- and phosphorylated, become commercially available, 
the study of additional mitotic kinases involved in oncogenesis, like PLK1, and 
their possible roles in E2-driven oncogenesis and further refinements in the 
targeting of specific entities, AurA and MDM2, with small molecule inhibitors. 
The ultimate goal of these studies was to identify early molecular and 
cellular changes during E2-induced oncogenesis that could provide new novel 
targets for the prevention and therapeutic intervention of human sporadic BC. 
The over-expression of the two oncoproteins AurA and MDM2 seemed likely 
initial starting points. Preliminary studies from our lab using the Aur kinase 
small molecule inhibitor MK-0457 (originally known as VX-680) in the ACI rat 
showed that while tumor incidence was unaffected, tumor multiplicity and size 
were significantly reduced (~60%) (Li S.A., 2008). In addition, preliminary 
studies in the Syrian hamster show that RITA has the ability to restore 
endogenous p53wt function. Both results, while preliminary, represent initial 
steps in the chemoprevention of E2-driven oncogenesis targeting specific 
entities. The over-expression of AurA and MDM2 appear to be early events 
during oncogenesis. Therefore, early intervention could hold the promise to 
effective tumor prevention by blocking the cascade of CA, CIN and 
aneuploidy. 
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